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ABSTRACT 
TRANSMURAL HETEROGENEITY OF CELLULAR LEVEL CARDIAC 
CONTRACTILE PROPERTIES IN AGING AND HEART FAILURE 
The left ventricle of the heart relaxes when it fills with blood and contracts to eject 
blood into circulation to meet the body’s metabolic demands. Dysfunction in 
either relaxation or contraction of the left ventricle can lead to heart failure. 
Transmural heterogeneity is thought to contribute to normal ventricular wall 
motion but it is not well understood how transmural modifications affect the failing 
left ventricle. The overall hypothesis of this dissertation is that normal left 
ventricles exhibit transmural heterogeneity in cellular level contractile properties 
and with aging and heart failure there are region-specific changes in cellular level 
contractile mechanisms. 
Age is the biggest risk factor associated with heart failure and therefore we 
investigated transmural changes in Ca2+ handling and contractile proteins in 
aging F344 rats before the onset of heart failure. We found that in 22-month old 
F344 rats there is a region-specific decrease in cardiac troponin I 
phosphorylation in the sub-epicardium that may contribute to slowed myocyte 
relaxation in the sub-epicardial cells of the same age. 
We then investigated the transmural patterns of contractile properties in 
myocardial tissue samples from patients with heart failure. Force and power 
output reduced most significantly in the samples from the mid-myocardial region 
when compared to sub-epicardium and sub-endocardium of the failing hearts. 
There was a region-specific increase in fibrosis is the mid-myocardium of the 
failing hearts. Myocardial power output was correlated with key sarcomeric 
proteins including cardiac troponin I, desmin and myosin light chain-1. 
The results in this dissertation reveal novel region-specific modifications in 
contractile properties in aging and heart failure. These transmural effects can 
potentially contribute to disruption in normal wall motion and lead to ventricular 
dysfunction
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Chapter 1.  Introduction 
1.1. Heart is a heterogeneous organ 
William Harvey, a 17th century physician, was one of the first to describe the 
heart as a muscular organ. He proposed that the function of the heart was to 
expel blood from the ventricles through contraction and relaxation. He described 
these findings in his book titled “On the motion of the heart and blood in animals” 
in 1628 1. Physician Richard Lower built upon Harvey’s work and described the 
anatomy of the heart in further detail in his book titled “ Tractatus de corde” in 
1669 2. He observed a complex arrangement of muscle fibers that formed 
“layers” and he speculated that the architectural complexity of the fibers were 
potentially important in the ejection of blood from the ventricles (Figure 1.1) 2. In 
the 19th century, James Pettigrew did an exhaustive study of the heart anatomy 
in several vertebrates and found that the muscle “layers” could be peeled from 
the outside (sub-epicardium) of the left ventricle to the inside (sub-endocardium) 
of the left ventricular chamber. He observed that the fiber directions changed with 
every muscle “layer” he removed 3. Intriguingly, the fibers in the middle “layers” 
were observed to be circumferentially arranged and were called “triebwerkzeug” 
which in the German language can be translated to “actuating fibers” because it 
was thought that these fibers were potentially important for ventricular ejection 4. 
These historical observations about the muscle “layers” and fiber angles were 
further supported in a study done by Streeter et al. in 1969 5. In this study, they 
dissected a through-wall transmural piece of the left ventricular wall and then 
 1 
histologically sliced them into 10 μm sections. This quantitative study showed 
that the muscle fiber arrangement shifted from -90° (relative to right-hand 
orientation) in the sub-epicardium, to ~0° in the mid-myocardium 
(circumferentially arranged fibers) to +90° in the sub-endocardium of the canine 
left ventricular wall (Figure 1.2 5). Similar muscle “layers” and fiber angles were 
reported in human left ventricles in a study done by Greenbaum et al. in 1981 6. 
All these observations from the past several centuries provide support for the 
distinct myocardial architecture across the ventricular wall. In the last 10 years 
sophisticated technologies like magnetic resonance diffusion tensor imaging are 
being used to visualize in detail the myocardial architecture and fiber angles in 
the ventricles 7. Furthermore, several studies have linked structural heterogeneity 
in myocardial architecture across the left ventricular wall to the function of the 
heart. For example, cardiac imaging and computational modeling of the heart 
have shown that transmural myocardial heterogeneity can influence wall 
thickening, ejection fraction (volume fraction of blood pumped out of the ventricle 
with each heart beat) 8 and ventricular torsion (an index of the “wringing” motion 
of the heart) 9, 10. Assessing myocardial heterogeneity in terms of cardiac function 
can be extremely useful when understanding human heart failure. 
1.1.1. Heart failure and the left ventricular wall 
Heart failure is a debilitating clinical syndrome in which the ventricles are unable 
to pump sufficient blood to meet the body’s metabolic demands. Currently, there 
are 5.1 million people in the United States who suffer from this syndrome. This 
 2 
population is on the rise because advancing age is the number one risk factor for 
heart failure and 1 in 5 Americans will be >65 years of age by 2050 11. 
The progression of heart failure is classified into stages A through D by the 
American College of Cardiology Foundation (ACCF) and American Heart 
Association (AHA) and/or stages I through IV by New York Heart Association 
(NYHA). ACCF/AHA classification provides information about the progression of 
structural changes in the heart and NYHA classification yields information about 
the diminishing ability of patients to carry out physical activities. Some of the 
symptoms of heart failure are shortness of breath, fatigue and edema 11. 
Heart failure can be divided into 2 groups-systolic heart failure and diastolic heart 
failure. In systolic heart failure the heart is not able to maintain cardiac output 
because of reduced ejection fraction (≤ 40%). In diastolic heart failure the 
ejection fraction is preserved (≥ 50%) but patients exhibit symptoms of heart 
failure such as, shortness of breath. Currently, it is much more difficult to 
diagnose diastolic heart failure but it is estimated that half of the patients with 
heart failure have diastolic dysfunction 11-13. 
There are several causes of heart failure, which include hypertension, ischemia, 
genetic mutations (mutations in at least 10 sarcomeric genes have been 
identified) 14-16 or the cause maybe idiopathic (unknown) 11. Even though the 
etiologies are varied there are common pathophysiological changes that occur in 
heart failure, called ventricular remodeling. Due to the complex nature of 
ventricular remodeling a consensus statement was released in the Journal of the 
 3 
American College of Cardiology stating “Cardiac remodeling may be defined as 
genome expression, molecular, cellular and interstitial changes that are 
manifested clinically as changes in size, shape and function of the heart after 
cardiac injury” 17. 
Ventricular remodeling can be adaptive at first but with progression of heart 
failure it can become maladaptive 17, 18. Depending on the stressors there can 
either be concentric hypertrophy (thickening of the left ventricular wall by addition 
of myocytes in parallel) or cardiac dilation/eccentric hypertrophy (thinning of the 
left ventricular wall through alignment of myocytes in series and enlargement of 
the ventricular chamber) 19, 20 (Figure 1.3). Any of these modifications can 
potentially affect the ventricular wall transmurally 21. 
1.1.1.1. End-stage heart failure 
There are ~50,000 patients with end-stage heart failure (classified as stage D or 
IV) at any given time in the United States. These patients have structural heart 
disease (mostly severely dilated ventricles 13, Figure 1.3) and are unable to 
carryout any physical activity 11. These patients generally have an ejection 
fraction of ≤ 20% 13. At this stage the options for therapy are few and involve 
chronic inotropes, mechanical circulatory support and/or heart transplant surgery 
11, 22. Due to the limited number of available donors there are only ~ 2300 heart 
transplants each year 11. 
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1.1.2. Imaging studies evaluating transmural ventricular wall function 
It is not fully understood how the left ventricle changes transmurally during heart 
failure. There are some imaging studies that have shown changes in fiber angle 
orientation 23, 24 with heart failure. For example, a study induced a myocardial 
infract in sheep and after 3 months excised the hearts and evaluated the hearts 
using diffusion tensor imaging. The authors showed that the mid-myocardial and 
the sub-epicardial fibers were disorganized and there were changes in fiber 
angles 25 that could ultimately lead to pump dysfunction. 
In a quest to find better prognostic tools, several clinical studies in patients with 
cardiac dysfunction have shown that the shortening of the middle transmural 
region (p=0.001) of the ventricular wall is a better predictor of cardiovascular 
death, myocardial infarction and stroke than shortening of the endocardial region 
(p=0.089) and the gold standard ejection fraction (p=0.085) (Table 1.1 26). These 
results are surprising because ejection fraction (a measure of global ventricular 
function used in standard clinical practice) was not a good predictor of clinical 
end-points when compared to midwall shortening, which is an indicator of 
ventricular wall motion. These imaging studies have shown that transmural 
effects are clinically important and may potentially be of better prognostic value in 
predicting clinical endpoints 26-30. However, the underlying mechanisms that give 
rise to these transmural effects are still unclear and may include tissue, cellular 
and molecular level heterogeneity in the ventricular wall. 
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1.1.2.1. Transmural tissue level changes in the ventricular wall  
The myocardium is predominantly made up of myocytes and cardiac 
fibroblasts 31. Cardiac fibroblasts are essential for extracellular matrix protein 
production and become hyperactive after injury or stress, which leads to fibrosis. 
Collagen protein makes up ~80% of the extra cellular matrix 31. With heart failure 
there maybe an increase in fibrosis 31, 32, replacement of myocytes with fibrotic 
tissue and myocyte disarray 18, 33, 34. These modifications can have detrimental 
effect on both the electrical and mechanical activity of the heart. For example 
studies have shown that discontinuities due to fibrosis can lead to conduction 
abnormalities and arrhythmias 34-36. The replacement of myocytes with fibrotic 
tissue can also reduce the number of force generating sarcomeres, which can 
ultimately lead to reduction in contractile function 37. 
Recent clinical studies have investigated the effect of the regional distribution of 
fibrosis through the ventricular wall and its effect on myocardial contractile 
properties using late gadolinium enhancement cardiovascular magnetic 
resonance. They found that midwall fibrosis may predict adverse cardiovascular 
outcomes in patients with cardiac dysfunction 38-40. These studies allude to a 
region dependent increase in fibrosis. However, few studies have investigated 
the regional distribution of fibrosis across the left ventricular wall and its effect on 
cellular level contractile properties. 
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1.1.3. Cellular and molecular level transmural heterogeneity 
Previous studies have demonstrated that there are distinct differences in action 
potential morphologies and action potential duration between the sub-
epicardium, mid-myocardium and sub-endocardium of the left ventricles in 
various mammals including humans 41. In heart failure there can be a reduction in 
the difference between the transmural action potential duration across the 
ventricular wall leading to arythmogenesis 42, 43. Some of these changes are due 
to modifications in expression of several cardiac transporters and ion channels 
across the ventricular wall 44. 
There are few reports in the animal-based literature which show that different 
regions of the left ventricular wall exhibit variable contractile properties 45 46 47. 
van der Velden et al. 47 isolated sub-epicardial and sub-endocardial samples from 
the left ventricular wall of pig hearts 3 weeks after an induced myocardial 
infraction or a sham operation. They found that maximum force decreased by 
35% in the sub-endocardial samples in the myocardial infract group when 
compared to sub-endocardial samples in the sham group. 
In summary, the heart is a heterogeneous organ evidenced by transmural 
differences in myocardial architecture and fiber angles 2-5. There are also cellular 
and molecular level differences which contribute to transmural differences in 
excitation of the left ventricular wall 36, 42-44. However, transmural changes that 
may contribute to cellular level contraction have not been explored in aging and 
human heart failure. 
 7 
1.2. Sarcomere function in the heart 
1.2.1. Contraction and sarcomeric proteins 
Sarcomeres are basic units of muscle, organized in series and in parallel in the 
cytosol of a myocyte. They are made up of thick and thin filaments, which slide 
past each other to undergo contraction 48, 49 (Figure 1.4). The z-disks of a 
sarcomere contains many different proteins including desmin, an intermediate 
filament protein which acts as a scaffold and connects sarcomeres at z-disks 50. 
Six titin proteins (the biggest protein in the human body, ~33 MDa) span from the 
z-disk to the m-line of the sarcomere 51. 
The cross bridge is a hexamer made up of two myosin heavy chains (MHC) 
whose tails polymerize with each other to form the thick filament. Attached to a 
MHC neck region are two proteins called the myosin light chain-1 (MLC-1) and 
myosin light chain-2 (MLC-2). On the head region of a MHC is an ATP binding 
site 52, 53 (Figure 1.4). 
The thin filament is made up of a polymerized actin backbone. Tropomyosin a 
filamentous protein winds itself around every 7th actin on the thin filament and 
blocks the actin binding sites from myosin in the relaxed state 54. Bound to 
tropomyosin is the troponin complex, which is made up of cardiac troponin T 
(cTnT) that binds to tropomyosin, cardiac troponin I (cTnI) which is the inhibitory 
unit that keeps actin and tropomyosin in place in the relaxed state, and cardiac 
troponin C (cTnC) which is the Ca2+ binding subunit 55 (Figure 1.4). 
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Before contraction can occur Ca2+ is released from the sarcoplasmic reticulum 
and binds to cTnC. This leads to a conformational change in cTnI which removes 
its inhibition and allows tropomyosin to move and expose the binding sites on 
actin for myosin to attach 56. Myosin hydrolyzes ATP and binds to actin and 
undergoes a power stroke sliding the thin and thick filaments past each other 
causing contraction. After contraction has occurred Ca2+ in taken up by the 
sarcoplasmic reticulum through the sarcoplasmic reticulum Ca2+-ATPase 
(SERCA) pump and thin filament proteins go back to their relaxed state. At the 
same time ATP binds to myosin allowing myosin to go back to its relaxed state 48, 
49, 52, 56. 
1.2.2. Mechanics of the heart 
The heart must perform work against an afterload on a beat-to-beat basis to 
maintain cardiac output. This is not an easy task because ventricular filling and 
ejection is not uniform for every beat. The heart is able to correct for these 
changes due to the Frank-Starling mechanism (Figure 1.5). This mechanism is 
the intrinsic ability of the heart to change the force of contraction and therefore 
cardiac output in response to alteration (increase or decrease) in the end 
diastolic volume 57. 
At the myocyte level, preload (the volume of blood during ventricular filling) 
stretches the myocytes, which in turn increase the sarcomere length. In this 
phase cytosolic Ca2+ concentration is ~100 nM and there are very few thick and 
thin filaments interactions. During contraction the Ca2+ concentration increase 
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upto ~1 μM which leads to thin filament activation 58. At this phase cross bridges 
are able to attach to actin and undergo a power stroke leading to myocyte 
shortening and force production. This action allows the heart to generate power 
and perform work against an afterload (aortic pressure) 55, 59. 
The process of contraction and relaxation are made of active and passive 
mechanical components. The active mechanical component is primarily due to 
the interaction of myosin motors on the thick filament with actin on the thin 
filament 60, 61. The passive component is primarily due the sarcomeric protein titin 
and extracellular matrix protein collagen 62. 
Furthermore, preload, afterload and contractility can all affect the Frank-Starling 
mechanism (Figure 1.5) of the heart and are highly regulated through alteration 
in content, isoform switch and posttranslational modifications of sarcomeric 
proteins 63. Therefore, dysfunction in sarcomeric proteins can lead to mechanical 
pump dysfunction 63 and thus contribute to diastolic and/or systolic heart failure. 
The modification in sarcomeric proteins and its functional consequence will be 
discussed further in Chapter 3, 4 and 5. 
1.3. Overall hypothesis and scope of this dissertation 
The overall hypothesis of this dissertation is that normal left ventricles exhibit 
transmural heterogeneity in cellular level contractile properties and with aging 
and heart failure there are region-specific changes in cellular level contractile 
mechanisms. 
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In Chapter 3, we investigate the adaptive limits of myocytes before the onset of 
heart failure in a rodent model of aging. We evaluate the biochemical status of 
proteins that are involved in Ca2+ handling and contraction from the sub-
epicardium, mid-myocardium and sub-endocardium of the left ventricular free 
wall of aging F344 rats. 
In Chapter 4, we investigate the mechanical properties of ventricular samples 
from patients with end-stage heart failure where the hearts had already become 
maladaptive. Functional measurements were performed in chemically 
permeabilized multicellular preparations. These biospecimens were optimal for 
testing myofibrillar-level function and for investigating the effects of the 
extracellular matrix on passive mechanical properties. We also investigate 
biochemical status of sarcomeric proteins and the extent of fibrosis in through-
wall left ventricular samples from the sub-epicardium, mid-myocardium and sub-
endocardium of non-failing and failing human hearts. 
In summary, we used both rodents and human biospecimens to investigate 
cellular and molecular modifications that affect properties involved in both 
relaxation and contraction across the ventricular wall to understand cellular level 
transmural effects in aging and end-stage heart failure.  
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Table 1.1. Predictors of cardiovascular endpoints. 
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Figure 1.1. An illustration of the spiral myocardial fibers. 
A sketch of the spiral myocardial fibers observed by Richard Lower from the 
anterior side of the heart (Figure 4, adapted from the book 
“Tractatus de corde”, 1669 2).  
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Figure 1.2. Photomicrographs of histological sections and fiber angles. 
Typical sequence of photomicrographs showing fiber angles in successive 
sections taken from a heart in systole. The sections are parallel to the epicardial 
plane. Fiber angle is +90° at the endocardium, running through 0° at the midwall 
to -90° at the epicardium. The sequence of numbers refers to deciles of wall 
thickness (left panel). Fiber angles for four sampling sites, a through d, in section 
from a heart in diastole are plotted as a function of percent wall thickens. Zero 
percent of wall thickness implies the endocardial surface. M represents the mean 
of the data at these four sites. (Figure 3 and 4, adapted from Street et al.1969 5) 
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Figure 1.3. Pathological changes with progression of heart failure. 
Dilated (left) and hypertrophied (right) heart showing left ventricular remodeling.
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Figure 1.4. Sarcomere. 
Schematics of the major sarcomeric proteins.  
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Figure 1.5. Frank-Starling mechanism of the heart. 
The curves show the change in cardiac output for a given ventricular diastolic 
volume when there is increased contractility (dark blue curve), in a normal resting 
heart (green curve) and in a failing heart (red curve). 
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Chapter 2. Methods 
2.1. Animal model and human cardiac tissue 
2.1.1. Aging F344 rats 
Female Fischer 344 rats were obtained from the National Institute on Aging 
colony maintained by Harlan (Indianapolis, IN). The rats purchased were of 6, 18, 
and 22 months of age (n=3 animals per age group). All animal procedures were 
approved by the University of Kentucky Institutional Animal Care and Use 
Committee and conformed to standards of the Guide for the Care and Use of 
Laboratory Animals. 
We harvested the heart from each animal by first injecting heparin (800 U IP) and 
then anesthetizing each animal with an intraperitoneal injection of pentobarbital 
(50 mg/kg). We dissected the chest wall to expose the thoracic cavity and 
excised the heart rapidly. This heart was then cannulated at the aorta and the 
coronary arteries were perfused with ice-cold Krebs Henseleit solution (in 
mmol/L: 113 NaCl, 4.7 KCl, 0.6 KH2PO4, 1.2 MgSO4, 12 NaHCO3, 10 KHCO3, 
10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES], 30 Taurine, 5.5 
glucose, and 10 2,3-butanedione monoxime [BDM]) until the perfusate ran clear 
of blood from the coronaries. 
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The heart were then hung from a Langendorff perfusion apparatus and 
enzymatically digested for 10–12 min at 37°C with digestion solution (Krebs 
Henseleit containing 10 mM BDM, 20 μM CaCl2, and 46 μg/ml Liberase TH, 
Roche Applied Science, Indianapolis, IN). After the initial digestion step, the left 
ventricular free wall was dissected and sectioned transmurally into three portions 
of equal thickness (sub- epicardium, mid-myocardium, and sub- endocardium), 
Figure 2.1 64. These tissues were then flash frozen in liquid nitrogen and then 
stored in -80°C for biochemical assays. 
A separate set of F344 animals of ages 6, 18 and 22 months were used to 
assess left ventricular function using echocardiography. These animals were 
later sacrificed and the hearts were excised and perfused in the same fashion as 
mentioned above but were not flash frozen. Tissues from the three different 
regions were digested further and single myocytes were isolated. Ca2+ transients 
and unloaded shortening contractions were measured using electrically-excitable 
myocytes from the sub-epicardial, mid-myocardial and sub-enodcardial regions 
of the hearts. A computational model was also generated to predict how the 
sarcomere length of an unloaded myocyte would change in response to an 
intracellular Ca2+ transient 65. These set of experiments were not a part of this 
dissertation but the results were used to make inferences about the biochemical 
results from the F344 aging rats. 
  
20 
 
 
2.1.2. Human cardiac biospecimens 
2.1.2.1. Procurement and cryo-preservation of biospecimens 
We obtained ventricular through-wall samples from patients undergoing heart 
transplants at the University of Kentucky and from organ donors who did not 
have prior history of heart failure through the Kentucky Organ Donors Affiliates 
(KODA). Figure 2.2 shows an external view of one donor and one failing human 
heart. We cut left ventricular tissue sections from the free wall just above the 
apex as soon as the heart was excised from the body by the surgeon and was 
passed to us. We then transported the tissue to the laboratory in specimen cups 
containing saline slush. We split the tissue sections transmurally into three parts 
of equal thickness to form the sub-epicardial, mid-myocardial and sub-
endocardial samples. These specimens were then placed in 2 mL cryogenic 
vials, flash-frozen in liquid nitrogen, and subsequently stored at -150°C in the 
vapor phase of liquid nitrogen. All procedures were approved by the University of 
Kentucky Institutional Review Board and subjects gave informed consent. 
2.1.2.2. Clinical characteristics of patients and donors 
We studied left ventricular tissue from patients in end-stage heart failure 
receiving heart transplants and from organ donors. We had 5 patients with non-
ischemic and 5 with ischemic heart failure in this study. The mean age of the 
patients with heart failure was 49 (range 20 to 65) while that of the organ donors 
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was 35 (range 18 to 59). Females donated 20% of the failing hearts and 50% of 
the non-failing organs. Data describing the patients and donors are shown in 
Table 2.2. 
2.2. Muscle mechanics 
We performed mechanical assays on chemically permeabilized multicellular 
preparations obtained from human hearts. We analyzed a total of 141 
multicellular preparations from 48 samples (3 transmural regions from each of 6 
non-failing and 10 failing human hearts). Jweied et al. showed that previously 
frozen and fresh tissue samples yield comparable data with these techniques 66. 
We saved the permeabilized samples that were not used for functional tests for 
subsequent biochemical assays. Following sub-sections describe the overview of 
the procedures to prepare and perform these biophysical assays. 
2.2.1. Solutions 
We used relaxing solution to isolate multicellular preparations that contained (in 
mmol L-1): 100 KCl, 10 imidazole, 4 ATP, 2 EGTA and 5 MgCl2 and two protease 
inhibitors (phenylmethylsulfonide 500 µmol L-1 and leupeption 40 µmol L-1). We 
used pCa (= -log10[Ca2+]) solutions for the mechanical experiments which 
contained (in mmol L-1): 20 imidazole, 14.5 creatine phosphate, 7 EGTA, 4 
MgATP, 1 free Mg2+, free Ca2+ ranging from 1 nmol L-1 (pCa 9.0) to 32 µmol L-1 
(pCa 4.5) and sufficient KCl to adjust the ionic strength to 180 mmol L-1. The 
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precise composition of each pCa solution was determined using Maxchelator 
software (version 2.50) and NIST stability constants 67. 
2.2.2. Chemically permeabilized multicellular preparations 
We obtained multicellular cardiac preparations as previously described for rat 
samples 68. We took frozen tissue specimens (~5 x 5 x 5 mm) acquired using the 
methods mentioned in section 2.1.2.1 and placed it in 10 ml of relaxing solution 
(see section 2.2.1 for solutions). We then mechanically disrupted the tissue using 
a tissue homogenizer (Polytron, Brinkman Instruments, Westbury, NY), and 
chemically permeabilized the tissue using Triton X-100 (30 min, 1% v/v). We then 
stored the permeabilized samples in relaxing solution at 4°C for upto 12 hours 
before use (Figure 2.3). 
2.2.3. Mechanical assays with varying Ca2+concentrations 
We attached individual preparations (Figure 2.4) between a force transducer 
(resonant frequency 600 Hz, model 403, Aurora Scientific, Aurora, Ontario, 
Canada) and a servo motor (step time 0.6 ms, model 312B, Aurora) by crimping 
their ends into metal troughs (shaped from 27 gauge tubing) with overlays of 4-0 
nylon monofilament as previously illustrated in Figure 1B of Campbell & Moss 69 
(Figure 2.3). The experimental temperature was 15°C. We stretched the sample 
in pCa 9.0 solution (see section 2.2.1 for solutions) by manually adjusting the 
manipulator holding the motor until the mean sarcomere length of the preparation 
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(measured by video microscopy) was within 1% of 2.20 µm. We estimated the 
cross-sectional area (2.17 ± 0.07 x 10-8 m2) from the video images by assuming 
that each preparation had a circular profile. Once the sarcomere length was set 
the average length of the preparations was calculated to be 688 ± 11 µm. If it is 
assumed that single human myocytes 70 have average dimensions of 100 x 25 x 
25 µm, and that the relative collagen content of the preparations ranged from 5 to 
58%, each myocardial preparation probably contained between 13 and 30 single 
myocytes. 
Initially each preparation was immersed in pCa 4.5 solution to maximally activate 
the sample. Once tension had attained steady-state, we subjected the muscle to 
3 ‘saw-tooth’ lengthening/shortening perturbations (magnitude 0.04 l0, velocity of 
0.12 l0 s-1, inter-perturbation interval 100 ms, where l0 is the muscle length) and a 
rapid shortening/re-stretch maneuver (0.2 l0, 20 ms duration) before it was 
returned to pCa 9.0 solution (Figure 2.5). This protocol has been described 
previously 68, 71. We subsequently performed similar trials for each preparation 
using solutions with pCa values ranging from 9.0 to 5.0. 
2.2.3.1. Tension-pCa curves 
Tension-pCa curves were generated with isometric force values measured in 
these trials and by fitting the raw data to an equation of the form 
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   (1) 
where A corresponds to passive force, B represents Ca2+ activated force, n is the 
Hill coefficient, and  is the free Ca2+ concentration required to develop 
half the maximum Ca2+-dependent force. 
2.2.3.2. Rate of tension recovery 
After the rapid shortening/re-stretch maneuver, the rate of tension recovery (ktr) 
was calculated by fitting a single exponential function to the recovery time-course 
as -ln(1/2)/(t1/2), where t1/2 is the time required for tension to rise from the Presid 
to 1/2(Pmax + Presid) and where Pmax is the maximum tension attained after 
restretch. Presid was defined as the minimum tension occurring after restretch 
(Figure 2 of Campbell, 2006 72). 
2.2.3.3. Short-range force and short-range stiffness  
Short-range force and short-range stiffness values were calculated for each 
stretch response at each level of Ca2+ activation. The short-range force is the 
non-linear force response due to strained cross bridges when the preparation is 
stretched by 4% of the original length at a speed of 0.12 l0 s-1after the preparation 
reached steady state. Short-range force was determined using the algorithm 
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illustrated in Figure 2A of Mitov et. al., 2009 68. Short-range stiffness values are 
expressed as Young’s Moduli and were calculated by fitting regression lines to 
the force responses measured during imposed 4% length changes 68. 
2.2.4. Force-velocity assays 
Once we completed the measurements at intermediate Ca2+ levels 
(section 2.2.3), the preparation was re-activated in the pCa 4.5 solution. After 
force had reached the steady-state for this condition, we initiated a sequence of 
trials in which the preparation was allowed to shorten for 75 ms against a variety 
of pre-set loads (Figure 2.6A). This technique was used to establish the 
preparation’s force-velocity curve. We determined the shortening velocity for 
each trial from the slope of a regression line fitted to the final 50 ms of the force 
clamp 73. The average r2 value for these lines was 0.991 which indicates that the 
velocity of interfilamentary movement was not markedly dependent on the total 
distance shortened 74, 75. 
A hyperbolic curve was fitted to the force-velocity data using Hill’s equation 
   (2) 
where F is the force at shortening velocity V, and F0 is the maximum isometric 
force 76. The constants a and b have dimensions of force and velocity 
respectively. Power values were calculated as the product of force and velocity 
(Figure 2.6B). 
( ) ( ) ( )0F a V b F a b+ ⋅ + = + ⋅
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We performed all mechanical tests using SLControl software 77. We performed 
curve-fitting and data analysis using custom software written in MATLAB 
(Mathworks, Natick, MA). 
2.3. Histology 
We evaluated the relative collagen content of human myocardial tissue studied in 
this work by picrosirius red staining and bright field imaging 78. 
The tissue samples were first transferred from long-term storage in the vapor 
phase of liquid nitrogen to a cryostat maintained at -26°C. The samples were 
then placed in 10 x 10 x 5 mm cryomolds and were covered with optimal cutting 
temperature (OCT) medium (Schaumburg, IL). We then cut the samples into 10 
µm sections and air dried them on glass slides for 1 hour at room temperature. 
The staining method used was similar to the one described by Hanley et al. 79. 
The slides were initially covered in Bouin’s fixative solution and incubated at 56ºC 
for an hour. Next, we rinsed the slides in deionized water and placed them for 2 
hours in a 0.1% Sirius red solution (w/v) dissolved in 1.3% saturated picric acid. 
We then washed the slides with 0.5% acetic acid, dehydrated in 95% and 100% 
ethanol, and finally equilibrated them in xylene 79. We then imaged the sections, 
which had an average cross-sectional area of ~16 mm2 in bright field 78 with a 
10x objective (Olympus BX61VS microscope) and analyzed the images using 
custom software written in MATLAB (The Mathworks, Natick, MA). For this work 
27 
 
 
we analyzed a total of 150 images (1-6 images from each region of each heart) in 
duplicate by observers who were blinded to the experimental groups. 
2.4. Biochemical assays 
2.4.1. Assessment of Ca2+ handling and sarcomeric proteins modified by 
aging in the myocardium of F344 rats 
2.4.1.1. Phosphorylation of sarcomeric proteins 
We examined the relative phosphorylation of selected sarcomeric proteins MLC-
2, cTnI, cTnT, and tropomyosin using gel electrophoresis (n = 3 animals/age 
group). We prepared the samples by homogenizing small pieces of ventricular 
tissue (described in section 2.1.1) in a urea-thiourea sample buffer (in mol L−1, 
8 Urea, 2 Thiourea, 0.075 M DTT, and 0.05 Tris-HCl, with 3% SDS w/v, pH 6.8) 
80. We measured the protein concentration in each sample using a Lowry protein 
assay (RC-DC kit, Bio-Rad, Hercules, CA). We then modified each sample by 
adding 0.03% Bromophenol blue and 30% glycerol before boiling it at 95°C for 3 
min and subsequently cooling it on ice. We then loaded precast polyacrylamide 
gels (Mini-Protean TGX 10%, 15-well combs, Bio-Rad) with 3 μl of each sample 
(protein concentration 1 μg/μl) and ran the gel at 200 V for 30 min. We stained 
each gel with Pro-Q Diamond phosphoprotein gel stain (Invitrogen, Carlsbad, 
CA), scanned the gel using a Typhoon Trio+ imager (GE Healthcare, Piscataway, 
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NJ), restained the gel with SYPRO Ruby (Invitrogen), and finally scanned the gel 
again. We quantified the phosphorylation levels by integrating the densitometry 
profile (ImageQuant TL software, GE Healthcare) of each band in the Pro-Q 
Diamond image and dividing that result by the corresponding integral calculated 
for the SYPRO Ruby stained image. We calculated relative phosphorylation 
levels for the different samples by normalizing to data obtained using an external 
control 81 myocardial sample that was run on each gel and which was 
subsequently expressed relative to the data for a single 6-month-old epicardial 
sample. 
2.4.1.2. Content of α- and β-MHC isoforms 
We determined the relative content of the α- and β-MHC isoforms in the tissue 
homogenates using gel electrophoresis. As described by Tikunov 82, we 
extracted myosin from the tissue homogenates using a buffer containing 100 mM 
KCl, 100 mM KH2PO4, 50 mM K2HPO4, 10 mM EDTA, 10 mM 
Na4P2O7·10H2O, 4 mM β-Mercaptoethanol and 5% (vol/vol) Triton X-100 (pH 
6.5, 4–8°C, 100-μl volume, 24 h). We then added Laemmli buffer (80 μl) to each 
sample, after which it was heated to 95°C for 4 min. We then resolved the treated 
samples using gels that were 60 × 80 × 0.75 mm and contained 7% acrylamide 
(50:1 with bis-Acrylamide) and 35% glycerol. We ran these gels at a constant 
current of 3.0 mA for ∼18 h at 4°C and subsequently silver stained the gels with 
a commercial kit (SilverStain Plus, Bio-Rad). We then obtained scanned images 
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using a conventional office scanner (V500 Photo, Epson, Long Beach, CA). We 
determined the relative content of each isoform by fitting the densitometry 
profiles with asymmetrical Gaussian functions using GelBandFitter software 
previously developed by our laboratory 83. 
2.4.1.3. Expression of SERCA2a 
In order to assess the expression of sarco-/endoplasmic reticulum Ca2+ ATPase 
(SERCA2a), we first took 4 μl of each sample (Urea-Thiourea sample buffer; 1 
μg/μl protein concentration) and loaded them onto precast polyacrylamide gels 
(Mini-Protean TGX 4–15%, 15-well combs, Bio-Rad). We ran each gel at 200 V 
for 30 min and subsequently transferred them onto a polyvinylidene difluoride 
membrane using a semi-dry transfer cell. We then probed the membrane with an 
antibody (sc-8094, Santa Cruz Biotechnology) to SERCA2a at a 1:1,000 
dilution  84. We then incubated the membrane with a fluorescent secondary 
antibody (Alexa Fluor 680 donkey anti-goat IgG, Life Technologies) at a 1:7,500 
dilution. Immunoblotted bands were visualized using a LI-COR Odyssey imaging 
system (LI-COR Biosciences, Lincoln, NE) and analyzed using Odyssey version 
3.0 software. As described above for the analysis of myofibrillar proteins, we 
calculated relative SERCA2a contents by normalizing to data from an external 
control sample that was run on each gel and subsequently expressed relative to 
the data for a single 6-month epicardial sample. This facilitated statistical 
analysis of data from multiple western blots. 
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2.4.2. Assessment of sarcomeric proteins modified by heart failure in 
humans 
We spun down and froze in eppendorf tubes, chemically permeabilized 
specimens that had been prepared for functional testing but were not used for 
that purpose for future biochemical assays. A total of 48 samples were 
biochemically analyzed in this study (3 regions from 6 non-failing and 10 failing 
hearts). 
Some posttranslational modifications are thought to be regulated on a beat to 
beat basis in living myocardium and may thus be sensitive to the precise 
experimental conditions 85. However, the biochemical data we reported here 
should be representative of the preparations that were analyzed in the functional 
measurements. 
2.4.2.1. Phosphorylation and content of sarcomeric proteins 
The relative content (titin, myosin, cMyBP-C, α-actinin, desmin, actin, cTnI, MLC-
1, and MLC-2 and phosphorylation status (titin, cMyBP-C, desmin, cTnI, MLC-1) 
of key sarcomeric proteins were evaluated using SDS-PAGE. 
We homogenized the samples in a urea-thiourea sample buffer and determined 
the protein concentration in the sample using a Lowry protein assay. We loaded 
precast polyacrylamide gels (Tris-HCl, 26 well, Bio-Rad, Hercules, CA) with 
samples containing 1 µg of protein. We ran each gel at 200 V for 55 minutes and 
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then stained them to assess phosphoproteins using Pro-Q Diamond stain and 
then re-stained with SYPRO Ruby to assess total protein content (as described 
in section 2.4.1.1). We calculated relative phosphorylation levels and relative 
protein contents by normalizing to data obtained for a non-failing sub-epicardial 
sample that was loaded onto every gel as a control 65. 
2.4.2.2. Assessment of titin isoform content and phosphorylation 
The relative contents and phosphorylation levels of the N2B and N2BA isoforms 
of titin was assessed using a vertical agarose gel system 86. The gel was cast 
using 1.2% w/v Sea Kem Gold Agarose, 30% v/v Glycerol, 0.05 M Tris-base, 
0.384 M Glycine, and 0.1% w/v SDS. We loaded the samples (3 µL at a protein 
concentration of 1 µg µL-1) on the gels and ran the gels at 4°C at a constant 
voltage of 40 V for the first 3hours, and then at 70 V for ~4 hours. We stained the 
gels with Pro-Q Diamond and SYPRO Ruby and analyzed them as described in 
section 2.4.1.1. We calculated relative phosphorylation levels and relative protein 
contents by normalizing to data obtained for a non-failing sub-endocardial 
sample that was loaded onto every gel as a control. 
2.4.2.3. Assessment of myosin heavy chain isoform content 
We assessed the relative expression of α- and β-MHC using specialized gels 
cast as described in section 2.4.1.2. We loaded the samples (3 µL at a protein 
concentration of 1 µg µL-1) made with urea-thiourea sample buffer onto the gels. 
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We used atrial samples as positive controls. We stained the gels with SYPRO 
Ruby stain for total protein and imaged and analyzed the gels as described in 
section 2.4.1.2. 
2.4.3. Site-specific phosphorylation of proteins 
We performed immunoblotting to assess the site-specific phosphorylation of cTnI 
and cMyBP-C. We performed experiments investigating the phosphorylation of 
cTnI at Ser23/24 using commercially available antibodies 87 (PSer23/24, antibody 
# 4004, Cell Signaling Technologies, Danvers, MA; cTnI, sc-52266, Santa Cruz, 
Dallas, TX). The antibodies we used to assess site-specific phosphorylation of 
cMyBP-C at Ser-273, Ser-282, and Ser-302 have been described by Govindan et 
al. 88. 
We ran samples (3 µL volume, at a protein concentration of 1 µg µL-1) on 10% 
precast polyacrylamide gels (Mini-Protean TGX, 15 well, Bio-Rad) for 30 minutes 
at 200 V and then transferred them onto polyvinylidene difluoride membranes. 
We first incubated each membrane with the primary antibody (1:1000 dilution) 
and then with the fluorescent secondary antibody (anti-mouse DyLight 680 for 
cTnI, PSer23/24 cTnI, and cMyBP-C; anti-rabbit 800 for phosphorylated cMyBP-
C, both antibodies from Cell Signaling Technologies) at a 1:7500 dilution. We 
subsequently visualized all bands using a LI-COR Odyssey imaging system (LI-
COR Biosciences, Lincoln, NE) and analyzed the bands using Odyssey V3.0 
image analysis software. 
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We calculated the relative phosphorylation of the site by integrating the 
densitometry profiles for the phosphorylated protein and total protein bands, and 
normalizing to data for a single rabbit muscle sample (for phosphorylated and 
total cTnI) or a non-failing sub-epicardial human sample (for phosphorylated and 
total cMyBP-C) that was loaded on to every gel as a control. 
2.5. Statistics 
We analyzed the experimental data in SAS 9.1.3 (SAS Institute, Cary, NC) using 
linear mixed effects models for A) the aging F344 rat study: incorporating 2 main 
effects (age and transmural region) and their interaction and B) the human heart 
failure study: incorporating 2 main effects (condition and transmural region) and 
their interaction. Post-hoc analyses were performed using the Tukey-Kramer 
method. 
We used the mixed effect model because there was a fixed and a random effect 
in the experimental designs. The animal ID/subject was a random effect while the 
transmural region was a fixed effect (the 3 discrete regions-sub-epicardium, mid-
myocardium and sub-endocardium). 
We assumed compound symmetry for the covariance structure because it is 
assumed that every observation collected from an animal/subject (random effect) 
was equally correlated with every other observation from the same subject. 
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Advantages of using the mixed effect model; for example in analyzing the 
mechanical experiments for the human heart failure study was that it accounted 
for an unbalanced design (6 non-failing and 10 failing hearts), allowed for 
repeated measures (the 3 regions for each subject came from the same heart, 
therefore the samples were spatially repeated) and the experiments were 
hierarchically nested (2-3 preparations from the same region). Furthermore, the 
linear mixed effects model method provided more statistical power than ANOVA 
when multiple samples are analyzed from each heart. 
Similar to a two –way ANOVA the interaction term in the linear mixed effect 
model tells us if one main effect depends on the other. For example, if the 
transmural regional pattern changes in the heart failure group when compared to 
the transmural regional pattern in the non-failing group for a given response then 
there is an interaction between the heart failure status and the transmural region. 
We also analyzed the biochemical data for the aging F344 rat study and the 
histology and biochemical data for the human heart failure study using the linear 
mixed model data. 
For the correlation plots, linear regression tests were performed in MATLAB 
(Mathworks, Natick, MA). For all statistical analysis p values less than 0.05 were 
considered significant. Data were reported as mean ± SEM. 
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Table 2.2. Clinical characteristics. 
A. Patients with heart failure  
Sex Age (y) Cardiomyopathy Medications 
F 49 Non ischemic, idiopathic Diuretic, Inotropes, Digoxin  
M 65 Ischemic 
Diuretic, ACE inhibitor/ARB, β-blockers, 
Inotropes, Digoxin, Statin, Insulin 
M 63 Ischemic 
Diuretic, ACE inhibitor/ARB, β-blockers, 
Statin 
M 49 Non ischemic, idiopathic Diuretics, Inotropes 
M 39 Non ischemic, idiopathic Inotropes, Statin 
M 64 Ischemic Diuretics, β-blockers, Inotropes, digoxin 
M 61 Ischemic 
Diuretic, ACE inhibitor/ARB, Inotropes, 
Statin - 
F 23 Non ischemic, postpartum 
Diuretic, ACE inhibitor/ARB, β-blockers, 
Inotropes 
M 20 Non ischemic, idiopathic Diuretic, ACE inhibitor/ARB, Digoxin 
M 53 Ischemic Diuretic, β-blockers, Inotropes, Digoxin 
B. Donors with Non-failing hearts  
Sex Age (y) Cause of death  
F 31 Stroke  
M 59 Stroke  
F 18 Head Trauma  
F 38 Stroke  
M 28 Head Trauma  
M 33 Head Trauma  
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Figure 2.1. Transmural dissection of the left ventricle of a rodent 
myocardium. 
(A) Schematic (top) and images (bottom) of separation of transmural regions 
from the LV free wall. After hearts were removed from the cannulae, the LV free 
wall was dissected (left) and separated into three transmural regions: sub-
epicardium (Epi), mid-myocardium (Mid), and sub-endocardium (Endo) of even 
thickness (Figure 1A, adapted from Chung et al., 2013 64). 
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Figure 2.2 External view of human hearts. 
A) Non-failing and B) failing heart. 
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Figure 2.3. Chemically permeabilized multicellular preparation. 
A frozen tissue sample from one region of the left ventricular heart was 
mechanically disrupted and chemically permeabilized and one multicellular 
preparation was tied between a force transducer and a motor. 
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Figure 2.4. Experimental preparations. 
A) Low and B) high magnification views of the central section of a representative 
myocardial preparation immersed in a solution with a pCa value of 9.0. 
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Figure 2. 5. Raw traces of the 3-stretch mechanical protocol with varying 
Ca2+concentrations. 
Representative A) force and B) length records for a multicellular preparation 
immersed in solutions with different free Ca2+ concentrations. The short-range 
force can be prominently observed as a non-linear force response to the first 
stretch (4% of l0). The rate of tension recovery (ktr) is the rate at which tension 
recovers after the shortening perturbation (20% of l0). 
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Figure 2.6. Force-velocity raw traces and curves. 
A) Superposed force and length records obtained during force-velocity 
experiments performed with a representative preparation isolated from a 
multicellular preparation B) Force-velocity (top) and Force-power (bottom) curves 
for the same preparation. Colors show the corresponding data. 
 
 
 
 
 
Copyright © Premi Haynes 2014  
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Chapter 3. Decrease in cardiac troponin I phosphorylation contributes to 
transmural pattern of myocyte relaxation that precede heart failure in aging 
F344 rats 
Aspects of this chapter were reported in the manuscript titled, “Altered ventricular 
torsion and transmural patterns of myocyte relaxation precede heart failure in 
aging F344 rats”. American Journal of Physiology: Heart and Circulatory 
Physiology, September 2013, 305:H676-H686. PMID: 23792678 
In this dissertation only the biochemical analysis and interpretation of the 
biochemical results pertaining to the functional and computational analysis will be 
discussed. 
3.1. Introduction 
The lifetime risk of developing heart failure is 20% for Americans ≥ 40 years of 
age 11, 12, 89, 90. Epidemiological studies show that ~ 50% of patients with heart 
failure have diastolic dysfunction and the prevalence of diastolic heart failure 
increases with age 91. Patients with diastolic dysfunction have preserved ejection 
fraction but their ventricles are unable to relax completely when filling with blood. 
Due to which the heart cannot maintain cardiac output and this can lead to heart 
failure (Figure 1.5). 
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Age associated structural modifications like increased myocardial fibrosis 92 and 
left ventricular remodeling 93 are thought to contribute to ventricular stiffness, a 
hallmark of diastolic dysfunction 91, 94. However, growing evidence suggests 
mechanisms more intrinsic to the myocyte. For example, our laboratory had 
previously reported that increased myocardial stiffness in aging F344 rats (an 
animal model of aging-associated heart failure 95, 96) are potentially due to 
attached cross bridges during diastole (defined as short-range stiffness) 68. 
Furthermore, the increase in ventricular stiffness correlated with the increased 
proportion of β-MHC in aging 68. Other studies have reported modifications in 
Ca2+ handling proteins and/or increase in expression of β-MHC to be involved in 
prolonged myocyte contraction and relaxation in older F344 animals 97, 98. 
Age-associated cardiovascular changes can be adaptive at first and potentially 
beneficial but with progression of age they can become maladaptive and lead to 
disease 7. Investigating the age-dependent modifications in myocyte function can 
therefore reveal aberrant mechanisms that precede heart failure. Furthermore, 
transmural cellular-level changes in the left ventricular wall with age could help 
us identify region-specific changes that are beneficial in understanding 
ventricular filling. 
 In this study, we examined F344 rodents at three ages: 6-, 18-, and 22-months. 
To study the effects of normal aging we investigated the myocardial properties 
between the 6- and 18-month old animals because F344 rats at these ages are 
largely free of systemic disease 95, 96. To detect the adaptive limit of myocardial 
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aging we studied the differences in myocardial properties between the 18- and 
22-month old animals. We did not study animals beyond the 22-month time point 
because by ~ 24-months of age F344 animals exhibit both systolic and diastolic 
dysfunction 95, 96 and high rates of mortality 99. We investigated the transmural 
changes that may occur in the sub-epicardium, mid-myocardium and sub-
endocardium of the left ventricle because transmural heterogeneity in the 
ventricular wall is thought to affect ventricular torsion 100, 101, a potential 
prognostic tool to detect diastolic dysfunction. 
We measured diastolic function and ventricular torsion using echocardiography. 
Ca2+ transients and unloaded cell shortening properties (time constant of Ca2+ 
decay (τCa), time to peak (TP) of unloaded sarcomere shortening, time from peak 
to 50% sarcomere re-lengthening (RT50)) were investigated using single 
myocytes isolated from the 3 transmural regions (sub-epicardium, mid-
myocardium and sub-endocardium) of the left ventricles of the 6, 18- and 22-
month old F344 animals (Figure 3.1). Molecular mechanisms that would predict 
slowed relaxation were simulated using computational modeling (Figure 3.3). As 
mentioned previously in section 2.1.1, these results can be reviewed in further 
detail in the published study 65. Here we will discuss the biochemical results that 
pertain to the functional properties measured. 
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3.2. Results 
We investigated the relative content and phosphorylation status of key 
sarcomeric proteins that may contribute to the slowed relaxation with aging. 
SERCA2a protein expression, assessed by Western blot and densitometry 
analysis (methods-section 2.1.1) revealed that the sub-endocardial samples from 
the 6-month old animals had significantly lower SERCA2a content than the sub-
epicardial (p=0.039) and the mid-myocardial (p=0.032) samples (Figure 3.4). 
Relative α- and β-MHC isoform expression was also measured in tissue 
homogenates (methods-section 2.1.1). The relative content of α-MHC trended 
downward with age, but the effect was not statistically significant (Figure 3.5). 
We used Pro-Q Diamond staining to measure the relative total phosphorylation of 
cTnI in our experimental samples (Figure 3.6). Post-hoc tests revealed that the 
22-month old sub-epicardial samples were significantly less phosphorylated than 
the mid-myocardial (p=0.037) and the sub-endocardial (p=0.016) samples of the 
same age (Figure 3. 7). Similar tests were performed for other myofilament 
proteins but we did not see any significant differences among the groups (Table 
3.1, 3.2, and 3.3). 
3.3. Discussion 
In the spectrum of heart failure progression, many studies focus on the extremes 
where the heart becomes maladaptive and heart failure is irreversible. If we can 
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identify mechanisms that precede overt heart failure then we can potentially treat 
it at an early stage. This study sought to identify transmural molecular level 
modifications that underlie myocardial and cellular level functional changes that 
occur in aging F344 rats. 
Our data not only confirmed an age-dependent change in cardiac function seen 
in prior studies 102 but also revealed a novel statistical age-region interaction with 
slowed relaxation in the F344 myocytes (Figure 3.1 and 3.2 65). Specifically, 
Figure 3.1 65 showed that the transmural regional pattern of relaxation properties 
(τCa-p=0.02, TP-p<0.05, RT50-p<0.001) were similar between the 6- and the 18-
month old animals. However, this transmural pattern was disrupted in the 22-
month old animals and the sub-epicardial myocytes from the 22-month old 
animals were affected the most (Figure 3.1 and 3.2 65). 
We studied the relative content of SERCa2a, a major Ca2+ handling protein as it 
could contribute to the alteration in τCa values (Figure 3.1 65). We found that there 
was a heterogeneous expression of SERCa2a in the 6-month old animals where 
both the sub-epicardial and mid-myocardial samples had significantly higher 
SERCa2a content than the sub-endocardial samples (Figure 3.4). This result 
qualitatively agreed with the increased τCa values (measure of Ca2+ decay) in 
both the 6-month sub-epicardial and mid-myocardial myocytes (Figure 3.1 65). 
This finding suggested that the increased expression of SERCa2a could 
potentially lead to an increase in Ca2+ uptake and therefore slower Ca2+ transient 
decay 103, 104. However, SERCa2a content did not seem to contribute to the 
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reduced τCa values in the 18- and 22-month old animals. This suggested the 
contribution of other mechanisms for example, phosphorylation of 
phospholamban (regulates SERCA) has been previously shown to reduce with 
age 105. 
When τCa-RT50 relationship was assessed in the sub-epicardial, mid-myocardial 
and sub-endocardial samples of all three age groups it was evident that the RT50 
of the 22-month old sub-epicardial cells was highly sensitive to τCa (Figure 3.2.) 
This meant that the slowed relaxation in the 22-month old sub-epicardial cells 
could be due to modifications in contractile proteins. In order to identify the 
molecular mechanisms simulations of unloaded sarcomere shortenings were 
performed to predict τCa-RT50 relationship. It was evident that alteration in the 
proportion of β-MHC isoform (which is known to modulate cross bridge 
kinetics  68, 106) did not change the relationship. However, the dissociation of Ca2+ 
from the troponin complex increased the slope of the τCa-RT50 relationship 
(Figure 3.3). 
We confirmed these predictions (Figure 3.3) by first investigating the relative 
expression of MHC isoform. We saw a qualitative decrease in the proportion of 
α -MHC isoform with age, similar to previous studies 68, 97 but we did not find any 
significant differences within groups (Figure 3.5). 
The effect of dissociation of Ca2+ from the troponin complex could not be tested 
directly but a previous study suggested that the decrease in phosphorylation of 
cTnI slows cardiac relaxation by reducing the rate at which Ca2+ unbinds from the 
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troponin complex 107. Therefore, we analyzed relative cTnI phosphorylation in the 
F344 animals. A significant decrease in phosphorylation of cTnI was found in the 
sub-epicardial samples when compared to the mid-myocardial and sub-
endocardial samples of the 22-month old animals (Figure 3.6 and 3.7). This 
biochemical result confirmed the computational prediction (Figure 3.3). Previous 
studies also support our results because cTnI phosphorylation has been shown 
to decrease with heart failure 108, 109 and can affect myocyte kinetics 107, 110 and 
Ca2+ sensitivity 108, 109. 
3.3.1. Conclusion 
In this study, the decrease in phosphorylation of cTnI seems to be an important 
modulator of myocyte relaxation in a region-specific manner of the aging F344 rat 
myocardium. Specifically, the reduced cTnI phosphorylation in the sub-epicardial 
cells contributes to the slowed relaxation observed in 22-month old sub-
epicardial cells. Both of these molecular and cellular level alterations in the sub-
epicardial cells may contribute to the reduction in ventricular torsion observed in 
these animals at 22-months 65. Together these results suggest that region-
specific changes in the left ventricular wall may precede heart failure and lead to 
diastolic dysfunction in aging F344 rats. 
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Table 3.1. Content of selected sarcomeric proteins. 
    Myosin Actin cTnT cTnI 
      
6-month old 
Epi 0.71±0.16 0.66±0.18 0.24±0.24 0.93±0.08 
Mid 0.70±0.09 0.82±0.25 0.47±0.09 0.68±0.08 
Endo 0.68±0.07 0.50±0.07‡ 0.48±0.27 0.58±0.05 
            
18-month old 
Epi 0.70±0.12 0.58±0.13 0.29±0.04 0.49±0.08 
Mid 0.60±0.05 0.58±0.08 0.25±0.08 0.62±0.09 
Endo 0.47±0.07 0.68±0.12 0.60±0.35 0.78±0.25 
      
22-month old 
Epi 0.54±0.09 0.81±0.24 0.43±0.14 0.70±0.18 
Mid 0.89±0.23 0.66±0.15 0.52±0.15 0.93±0.35 
Endo 0.57±0.05 0.41±0.03§ 0.28±0.03 0.81±0.09 
            
Main statistical 
effects and 
interaction 
(p values) 
Age 0.676 0.967 0.965 0.617 
Region 0.174 0.147 0.928 0.942 
Age *Region 0.223 0.132 0.165 0.259 
Protein contents are expressed in arbitrary units and were calculated by normalizing to data 
obtained for each protein from a 6-month old sub-epicardial sample that was loaded onto 
every gel as a control. Different from the sub-epicardial region of the same condition: § 
p<0.05. Different from the mid-myocardial region of the same condition: ‡ p<0.05. 
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Table 3.2. Content of selected sarcomeric proteins. 
    Tropomyosin MLC-2 MLC-1 
     
6-month old 
Epi 0.51±0.25 0.49±0.27 0.76±0.22 
Mid 0.53±0.18 0.49±0.15 0.74±0.12 
Endo 0.41±0.08 0.17±0.02 0.68±0.08 
          
18-month old 
Epi 0.29±0.04 0.15±0.01 0.48±0.03 
Mid 0.46±0.10 0.31±0.12 0.56±0.21 
Endo 0.46±0.10 0.36±0.04 0.61±0.12 
     
22-month old 
Epi 0.35±0.13 0.34±0.15 0.43±0.18 
Mid 0.43±0.10 0.57±0.28 0.72±0.33 
Endo 0.32±0.04 0.19±0.05 0.70±0.11 
          
Main statistical 
effects and 
interaction 
(p values) 
Age 0.770 0.763 0.658 
Region 0.363 0.160 0.565 
Age *Region 0.567 0.285 0.764 
Protein contents are expressed in arbitrary units and were calculated by 
normalizing to data obtained for each protein from a 6-month old sub-epicardial 
sample that was loaded onto every gel as a control. 
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Table 3.3. Phosphorylation of selected sarcomeric proteins. 
 
 
Phospho 
cTnT 
Phospho 
Tropomyosin 
Phospho 
MLC-2 
     
6-month old 
Epi 1.11±0.26 1.87±0.56 1.46±0.30 
Mid 0.95±0.31 1.32±0.132 2.09±0.35 
Endo 1.90±0.62 1.69±0.21 2.11±0.38 
      
18-month old 
Epi 0.85±0.41 2.05±0.27 2.79±0.73 
Mid 1.50±0.81 1.57±0.27 2.07±0.12 
Endo 1.25±0.72 1.34±0.32 1.55±0.17 
     
22-month old 
Epi 0.87±0.40 2.98±1.66 1.79±0.75 
Mid 1.22 ±0.26 2.20±0.38 1.27±0.18 
Endo 1.80±0.24 2.24±0.17 2.17±0.64 
     
Main statistical 
effects and 
interaction 
(p values) 
Age 0.965 0.364 0.433 
Region 0.165 0.368 0.885 
Age *Region 0.689 0.971 0.313 
Phosphorylation levels are expressed in arbitrary units and were calculated by 
normalizing to data obtained for each protein from a 6-month old sub-epicardial 
sample that was loaded onto every gel as a control. 
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Figure 3.1. Transmural patterns of Ca2+ handling and contraction dynamics 
are altered with age. 
A) Mean values (±SEM) of the time constant of F340/380 decay after peak (τCa) for 
each age-region group. (B, C) Same as panel A but showing time-to-peak (TP) 
unloaded sarcomere shortening and time from peak to 50% sarcomere re-
lengthening (RT50). * p < 0.05 vs. cells from the same region at 6 months of age. 
† p < 0.05 vs. endocardial cells at the same age. ‡ p < 0.05 vs. midmyocardial 
cells at the same age.  
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Figure 3.2. Aging alters Ca2+-relaxation coupling in epicardial myocytes. 
Plotted points show RT50 vs. τCa for each cell in the study, grouped according to 
region and animal age. Analysis of covariance on τCa-RT50 relations indicates 
that the slope depends significantly on the age-region group (p < 0.001). RT50 in 
epicardial myocytes from 6-month-old rats was significantly less sensitive to τCa 
than in 18- and 22-month-old cells from the same region. 
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Figure 3.3. Computer simulations of unloaded sarcomere shortening.  
Ca2+ transients with various rates of decay (τCa) were used as inputs to predict 
relationships between τCa and RT50 (time from peak shortening to 50% re-
lengthening) under different conditions. A) Example input Ca2+ transients of 
increasing τCa and corresponding SL outputs for the baseline model (40% β-
MHC, TnC Ca2+ affinity 0.3 μmol L-1). B) Sensitivity of the τCa-RT50 relation to 
doubling and halving relative β-MHC content. C) Sensitivity of the τCa-RT50 
relation to a 20% increase in TnC Ca2+ affinity. 
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Figure 3.4. Expression of SERCa2a. 
A) Representative immunoblots showing SERCa2a expression in F344 rats. B) 
Symbols show the mean SERCa2a measured for each region for each heart. 
A.U. stands for arbitrary units. In this figure, and in all similar panels, thin lines 
join data points from the same heart. Thick bars show the mean data for the 
region. The text above the plot shows p values for the main statistical effects. 
Significant differences between regions, tested separately for the three ages, are 
listed in the inset box. Significant differences due to aging, tested separately for 
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each region, are indicated by asterisks (* indicates p<0.05, ** indicates p<0.01, 
*** indicates p<0.001). 
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Figure 3.5. Shift in MHC isoform. 
A) Representative bands from mid-myocardial samples of various ages showing 
separated α- and β-MHC isoforms and B) the mean α-MHC isoform percentages 
across groups.  
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Figure 3.6. Broadrange gel stained for phosphorylated and total sarcomeric 
proteins. 
Two images of a single representative gel stained with Pro-Q Diamond (left) and 
SYPRO Ruby (right). The Pro-Q Diamond stain is more sensitive to 
phosphoproteins while SYPRO Ruby indicates total protein content. 
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Figure 3.7. Decreased cTnI phosphorylation in 22 month old sub-epicardial 
samples. 
A) Symbols show the mean Phospho cTnI measured for each region for each 
heart using Pro-Q Diamond (phospho-sensitive stain). A.U. stands for arbitrary 
units. 
 
 
 
 
 
 
Copyright © Premi Haynes 2014  
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Chapter 4.  Transmural heterogeneity of cellular level contractile function in 
human heart failure 
Aspects of this chapter will be reported in the manuscript titled, “Transmural 
heterogeneity of cellular level power output is reduced in human heart failure”. 
Journal of Molecular and Cellular Cardiology, accepted. 
DOI:10.1016/j.yjmcc.2014.02.008  
4.1. Introduction 
Clinical studies have shown that transmural variation in the contractile function of 
human myocardium may influence clinical end-points 26, 28. For example, a study 
by Wachtell et al. 26 followed 840 patients for 3,914 patient-years and showed 
that shortening of the middle transmural region of the left ventricular free wall is a 
better predictor of cardiovascular death, myocardial infarction, and stroke, than 
the shortening of other regions, or ejection fraction. However, the mechanisms 
that underlie these results, which may include transmural variation in cellular and 
molecular properties, are not well understood. 
Previous studies using human hearts have demonstrated that action potentials 
and Ca2+ transients vary systematically across the left ventricular free well, and 
that these effects probably reflect transmural-region specific expression of ion 
channels and ionic transporters 43, 44. There are a few reports in the animal-based 
literature showing that tissue samples from different parts of the ventricular wall 
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(specifically the sub-epicardial, mid-myocardial, and sub-endocardial regions) 
express different sarcomeric proteins and exhibit variable contractile 
properties  97, 100, 101, 111. Less is currently known about potential transmural 
variation in contractile function. Therefore, the goals of our study was to test the 
hypotheses that human hearts exhibit transmural heterogeneity of cellular level 
contractile properties, and that heart failure produces region-specific changes in 
contractile function. In order to evaluate both the active and passive mechanical 
properties of the tissue samples, we performed experiments using multicellular 
chemically permeabilized preparations. 
The results showed that cellular level indices of systolic function (power output 
and isometric force) exhibit transmural heterogeneity in non-failing human hearts. 
Specifically, samples from the mid-myocardium developed more power and more 
force than samples from the sub-epicardial and sub-endocardial regions. Heart 
failure reduced power and force by ~20% but affected mid-myocardial samples 
more than tissue from the other regions. As a result, failing hearts exhibited less 
transmural heterogeneity. Additional data from histological and biochemical 
assays suggested that these contractile changes reflect a region-specific 
increase in fibrosis and modifications to the content and phosphorylation status 
of sarcomeric proteins including cTnI, desmin and MLC-1. 
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4.2. Results 
4.2.1. Power output 
We measured maximum power output, an in vitro index of systolic function, using 
multicellular permeabilized preparations (Figure 2.4 and 4.1). Figure 4.2A shows 
force-velocity and force-power curves that we measured using preparations 
obtained from the sub-epicardial, mid-myocardial and sub-endocardial regions of 
one non-failing and one failing heart. In the non-failing samples, peak power 
output was higher for the mid-myocardial sample than it was for the sub-
epicardial and sub-endocardial samples (lower left panel). The failing samples 
exhibited less transmural variation (lower right panel). 
Figure 4.2B shows collated data for the 6 non-failing and 10 failing hearts. We 
found a significant interaction (p=0.030) between region and heart failure 
condition, which implies that the heart failure status affects the sub-epicardial, 
mid-myocardial, and sub-endocardial regions in different ways. Maximum power 
output was significantly lower (p=0.009) for the heart failure samples 
(0.37 ± 0.02 µW mg -1) than for the non-failing samples (0.50 ± 0.03 µW mg -1). 
The post-hoc tests revealed that in the non-failing samples, the maximum power 
output of the mid-myocardial preparations (0.59 ± 0.06 µW mg -1) was greater 
than that of the sub-epicardial (0.46 ± 0.03 µW mg -1, p value=0.021) and the 
sub-endocardial preparations (0.46 ± 0.04 µW mg -1, p value=0.015). We 
observed no significant transmural differences in the heart failure samples. Heart 
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failure thus lowered the power output of mid-myocardial samples more than it 
lowered the power output of sub-epicardial and sub-endocardial preparations. 
4.2.2. Isometric force 
Figure 4.3A shows that the isometric force also exhibited transmural variation in 
non-failing hearts and that the transmural pattern of variation was altered by 
heart failure (p<0.001). Since power is the product of force and velocity, these 
data suggest that the transmural variation in power output primarily reflects 
changes in force-generating capacity rather than changes in shortening velocity 
(which did not exhibit significant differences, Figure 4.3B). Heart failure lowered 
isometric force values normalized to cross-sectional area from 
12.27 ± 0.61 kN m-2 to 9.78 ± 0.37 kN m2 (p=0.042).  Post-hoc analysis showed 
that the non-failing samples exhibited transmural heterogeneity. Specifically, the 
maximum force generated by samples from the mid-myocardium 
(14.3 ± 1.33 kN m2) was higher than the force generated by the sub-epicardial 
(10.96 ± 0.74 kN m-2, p=0.008) and the sub-endocardial (11.47 ± 0.86 kN m-2, 
p=0.026) preparations. In these experiments, the samples from the failing hearts 
also exhibited heterogeneity, with the mid-myocardial preparations generating 
the least amount of force (8.80 ± 0.09 kN m-2). Heart failure thus lowered the 
force generating capacity of the mid-myocardial preparations more than that of 
the sub-epicardial and sub-endocardial samples. 
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4.2.3. Calcium sensitivity 
Figure 4.4A shows normalized isometric tension plotted as a function of the 
activating Ca2+ concentration (where pCa = -log10[Ca2+]) for preparations from the 
three transmural regions of non-failing (left panel) and failing (right panel) hearts. 
In the non-failing samples, Ca2+ sensitivity (assessed as the Ca2+ concentration 
required to produce half the maximum force) was 0.075 pCa units greater in the 
sub-endocardial samples than in the sub-epicardial samples (p=0.010, Figure 
4.4B). No transmural differences were observed in the failing samples. The 
progressive transmural change in calcium sensitivity that occurs in non-failing 
hearts is thus disrupted by heart failure (interaction term, p=0.047). 
4.2.4. Short-range components 
Figure 4.5A shows that the short-range stiffness exhibited transmural variation in 
non-failing hearts and that the transmural pattern of variation was altered by 
heart failure (p<0.001). Post-hoc analysis showed that the non-failing samples 
exhibited transmural heterogeneity. Specifically, short-range stiffness of samples 
from the mid-myocardium was higher than short-range stiffness of samples from 
the sub-epicardium (p=0.026). Samples from the failing hearts also exhibited 
transmural heterogeneity. The mid-myocardial samples were the least stiff and 
significantly different than the sub-epicardial samples (p=0.016). We did not find 
significant interaction between region and heart failure status for relative short-
range force (p=0.475, Figure 4.5B). These results suggest that heart failure 
65 
 
 
lowered the short-range stiffness in the mid-myocardial preparations more than 
the sub-epicardial and sub-endocardial samples suggesting a decrease in 
myocardial stiffness due attached cross bridges. 
4.2.5. Rate of tension redevelopment 
The rate of tension redevelopment was plotted as a function of relative tension 
for both the non-failing and failing samples from different transmural regions 
(Figure 4.6). We did not find any significant difference in the rate of tension 
redevelopment (ktr) at high Ca2+ concentration (pCa 4.5) with heart failure status 
or region (Figure 4. 7A). However, we found that there was a region dependence 
(p=0.008) in ktr at submaximal level of Ca2+ (pCa 5.7). Furthermore, the sub-
endocardial samples of failing hearts had significantly slower ktr than the sub-
epicardial (p=0.009) and the mid-myocardial (p=0.001) samples of the failing 
hearts (Figure 4. 7 B). 
4.2.6. Collagen content 
Figure 4.8 shows representative images of myocardial sections that had been 
stained with picrosirius red. Quantification showed that there was a significant 
interaction (p=0.020), which implied that heart failure affected the regions 
differentially. Heart failure also increased the proportion of tissue that was 
collagen from 0.103 ± 0.007 to 0.219 ± 0.012 (p=0.021, Figure 4.9A). Unlike the 
non-failing samples (which were not transmurally heterogeneous), the sections 
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cut from the three transmural regions of failing tissue all had collagen contents 
that were significantly different from each other (p values for all post-hoc tests < 
0.05). In the failing samples, the collagen to tissue ratio in the mid-myocardial 
sections was greater than that in the sub-epicardial and sub-endocardial sections 
by ~0.117 and ~0.041 respectively. 
The collagen to tissue ratio in the stained sections was negatively correlated with 
the relative contents of actin (Figure 4.9B) and myosin (Figure 4.9C) in wet tissue 
samples from the same biospecimens. This is consistent with a mechanism in 
which myocytes are replaced by extracellular matrix proteins when fibrosis 
develops. 
4.2.7. Modifications in sarcomeric proteins 
We investigated the potential changes in the isoform content and 
posttranslational status of sarcomeric proteins using gel electrophoresis and 
western blotting (see methods-section 2.4). The key findings were that heart 
failure status decreased the relative content of cTnI (p=0.021, Figure 4.10 and 
4.11A), reduced relative phosphorylation of cTnI at Ser23/24 (p=0.012) in the 
failing samples (Figure 4.12), increased the content of desmin protein (p<0.001, 
Figure 4.10 and 4.13A), reduced desmin’s relative level of phosphorylation 
(p=0.006, Figure 4.10 and 4.13B), and increased the relative content of N2BA 
isoform of titin (p=0.047, Figures 4.14). 
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No other statistically significant effects of heart failure status and/or transmural 
region were revealed by the linear mixed model analyses (Tables 4.1, 4.2, 4.3, 
4.4 and 4.5). 
4.2.7.1. Cardiac troponin I 
Cardiac troponin I (cTnI) content was reduced by 23% in samples from heart 
failure patients (p=0.021, Figure 4.10 and 4.11A). There was a region dependent 
difference in phosphorylation of cTnI (p=0.041). Post-hoc analysis showed that 
the sub-epicardial region was more phosphorylated than the sub-endocardial 
region of the heart failure group (p=0.004). The relative phosphorylation of cTnI 
at Ser23/24 was also reduced (p=0.012) in the failing samples (Figure 4.12). 
4.2.7.2. Desmin 
Heart failure increased the content of desmin protein (p<0.001, Figure 4.10 and 
4.13A) but reduced its relative level of phosphorylation (p=0.006, Figure 4.10 and 
4.13B).  
4.2.7.3. Cardiac myosin binding protein-C 
There was no significant difference in total phosphorylation of cMybp-c and its 
content (Tables 4.1 and 4.4). However, western blotting with a site-specific 
antibody showed that the phosphorylation of cMyBP-C at Ser302 depended on 
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transmural region (p=0.014, Figure 4.15). In non-failing hearts, this residue was 
also more phosphorylated in samples from the sub-epicardial region than in 
tissue from the mid-myocardium (p=0.047, Figure 4.15B). 
4.2.7.4. Titin 
Titin isoform content was also altered by heart failure. The relative amount of this 
protein expressed as the larger N2BA isoform increased from 0.541 ± 0.028 in 
the non-failing samples to 0.653 ± 0.022 in the samples from failing hearts 
(p=0.047, Figure 4.14A and B). Sub-endocardial preparations from failing hearts 
also exhibited higher levels of N2BA phosphorylation than sub-epicardial 
(p=0.006) and mid-myocardial (p=0.037) preparations (Figure 4.14C).  
4.2.8. Molecular mechanisms influencing contractile function 
Most of the functional parameters we measured in this work exhibited large 
within-group variability. For example, the power output of mid-myocardial 
preparations from non-failing hearts ranged from 0.443 to 0.747 µW mg-1, a span 
of 51%. We therefore used linear regression tests to test whether changes in the 
content and posttranslational status of sarcomeric proteins could explain the 
variance of the functional measures. This analysis revealed 24 relationships with 
p values less than 0.05. These relationships are shown in Tables 4.6 and 4.7 and 
Figures 4.16 and 4.17. 
69 
 
 
4.2.8.1. Power output 
Figure 4.16A shows that power increased with the relative content of cTnI 
(p=0.042). Figure 4.16B and C show that power decreased with the relative 
content of desmin (p=0.041) but increased with its relative phosphorylation 
(p=0.046). Finally, Figure 4.16D and E show that power increased with the 
relative content of MLC-1 (p=0.034) but decreased with the molecule’s relative 
phosphorylation (p=0.006). 
4.2.8.2. Rate of tension redevelopment 
At maximal Ca2+ activation ktr was significantly correlated with thick filament 
associated proteins. Figure 4.17A and B show that ktr increased with cMyBP-C 
(p=0.002) and decreased with its phosphorylation (p=0.031). Figure 4. 17C and 
D show that ktr increased with MLC-1 content (p<0.001) and its phosphorylation 
(p=0.013) and Figure 4.17E shows that ktr increased with MLC-2 (p=0.001). 
Other significant correlations between ktr and other sarcomeric protein are listed 
in Table 4.6. 
4.2.8.3. Other functional-biochemical relationships 
Table 4.7 shows that force (p=0.045) increased with the relative content of cTnI. 
Resting tension was positively correlated with the relative phosphorylation of cTnI 
at Ser23/24 (p=0.006) which suggests that this residue may influence the 
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mechanical properties of titin and/or the regulation of binding sites for myosin on 
the actin filament. The relative phosphorylation of cMyBP-C at Ser282 (p=0.001) 
and at Ser273 (p=0.023) predicted the maximum shortening velocity of the 
preparations. These posttranslational modifications are mediated primarily by 
PKA 112 and this kinase is known to increase the maximum shortening velocity of 
rat myocardium 113. However, the specific relationships between the 
phosphorylations of Ser282 and Ser273 and shortening velocity are new findings. 
4.3. Discussion 
Clinicians already recognize the significance of transmural variation in contractile 
function. For example, imaging studies have shown that shortening of the middle 
transmural region is a better predictor of cardiovascular death than traditional 
measures of global ventricular function such as ejection fraction 26, 28. The 
American Society of Echocardiography also notes in its guidelines that 
“Contraction of muscle fibers in the LV midwall may better reflect intrinsic 
contractility than contraction of fibers at the endocardium” 114. Our current work 
reveals four new cellular and molecular level results that may help to explain 
these clinically-relevant observations 26, 28. 
First, non-failing human hearts exhibit transmural heterogeneity of contractile 
properties (Figures 4.2- 4.4). Second, heart failure depresses power and force 
and has its biggest negative impact on mid-myocardial tissue. Failing hearts thus 
exhibit less transmural heterogeneity in cellular level contraction than non-failing 
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hearts (Figures 4.2 and 4.3). Third, human heart failure produces more fibrosis in 
mid-myocardial tissue than it does in sub-epicardial and sub-endocardial 
samples (Figure 4.9). This may explain why heart failure produces the greatest 
contractile deficits in the mid-myocardium as the additional connective tissue is 
likely to displace functioning myocytes. Fourth, power and rate of tension 
redevelopment correlate with the relative content and relative phosphorylation of 
key sarcomeric proteins (Figure 4.16 and 4.17 and Table 4.7). Therefore, 
therapies targeting these proteins may be particularly effective treatments for 
human heart failure. 
4.3.1. Region-specific modifications in systolic function  
During systole, the heart contracts against its afterload to eject blood from the 
ventricle. This can be mimicked in vitro by allowing permeabilized myocardial 
preparations to shorten against a controlled force 115 (Figure 4.1). The power 
output for each load is calculated by multiplying the force that the muscle 
generates by its shortening velocity. Figure 4.2 shows that the maximum power 
output exhibited significant transmural variation in non-failing hearts and was 
reduced by ~25% in failing organs (p=0.009). Further analysis suggests that 
these effects primarily reflect altered force generation (Figure 4.3A) since 
maximum shortening velocity was not influenced by heart failure status or 
transmural region (Figure 4.3B). 
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No previous studies have used human samples to assess transmural variation in 
power output. However, a few studies have measured the effect of heart failure 
on isometric force generation, with potentially conflicting results. For example, 
separate studies using epicardial biopsies 116 and samples from unspecified 
regions of the heart 117 have shown that isometric force is reduced by ~80% in 
patients with heart failure. Other works, using samples from unspecified regions 
of the left ventricle, suggests that there is no significant effect of heart failure on 
maximum isometric force 118-120. In the present experiments, heart failure reduced 
the average force generated by the experimental preparations (Figure 4.3A, 
p=0.042). However, post-hoc analysis of the different transmural regions showed 
that the effect was only significant for the mid-myocardial samples (p<0.001) and 
that heart failure did not significantly reduce the force generated by the sub-
epicardial (p=0.935) or the sub-endocardial (p=0.120) preparations. These 
results imply that heart failure influences force generation in a transmural specific 
manner in humans. Researchers developing future studies in this area may 
therefore wish to consider including transmural region as an independent 
grouping factor when they design their experiments. 
4.3.2. Failing hearts have increased mid-myocardial fibrosis 
Increased fibrosis was an important factor in these experiments. Figure 4.9A 
show that heart failure increased the relative content of collagen in the 
myocardial sections, and that the mid-myocardial samples of the failing hearts 
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contained more collagen than the matching sub-epicardial (p<0.001) and sub-
endocardial (p=0.043) sections. Increased collagen was also associated with 
lower relative contents of actin and myosin (Figure 4.9B-C). Additional analyses 
showed that force (p=0.325, Figure 4.18A) and maximum power p=0.012, Figure 
4.18B) were correlated with actin content. Together these data support the 
hypothesis that in human heart failure, increased fibrosis depresses contractile 
function by replacing myocytes with extracellular matrix proteins. 
The increased fibrosis might have been expected to raise passive force in the 
samples from the failing hearts. However, linear mixed model analyses showed 
that neither passive force (Figure 4.19A) nor passive stiffness (Figure 4.19B) at a 
sarcomere length of 2.2 µm were influenced by heart failure status or transmural 
region (all main statistical effects > 0.05). This probably reflects a compensatory 
effect of titin isoform expression. Consistent with previous studies 121, 122, 
samples from failing hearts had a greater relative content of the large N2BA 
isoform of titin (p=0.047, Figure 4.14B). This isoform shift tends to decrease 
passive stiffness and seems to counteract the mechanical effect of increased 
fibrosis in the samples from the failing hearts. 
Titin phosphorylation has also been shown to change passive stiffness 123. 
Although phosphorylation of N2BA isoform of titin did not change with heart 
failure (condition p=0.825, Figure 4.14C), the experimental data revealed a novel 
transmural heterogeneity. Sub-endocardial samples from failing hearts had 
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greater levels of phosphorylation than samples from the other regions (p=0.037 
versus mid-myocardium, p=0.006 versus sub-epicardium, Figure 4.14C). 
Another aspect of myocardial stiffness comes from the cross bridges that remain 
attached to the actin filaments during diastole. In this study short-range stiffness 
was significantly lower in heart failure (Figure 4.5A). The combined functional 
data of passive stiffness and short-range stiffness suggests that the failing 
myocardial samples may not be stiff. This is possible because most of the failing 
hearts in this study were dilated and dilated ventricles are thought to be 
compliant 124. 
4.3.3. Region-specific Modification in Ca2+ sensitivity 
In vivo function may be particularly sensitive to changes in Ca2+ sensitivity 
(defined as the free Ca2+ concentration required to generate half-maximum force) 
since myocytes are not maximally activated during a normal heartbeat. According 
to a Chapter 3, transmural variation in Ca2+ sensitivity may also modulate 
ventricular torsion 65. In the present experiments (Figure 4.4) non-failing samples 
exhibited a statistically significant increase in Ca2+ sensitivity (p=0.010, 
ΔpCa50=0.075) going from the sub-epicardial to the sub-endocardial 
preparations. However, samples from failing hearts did not show a significant 
transmural trend. 
Two previous studies using human myocytes isolated from unspecified 
ventricular locations have shown that Ca2+ sensitivity increases with heart failure 
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108, 125. Another study 117 documents no change. Again, similar to the previous 
discussion relating to isometric force generation, it is difficult to interpret these 
data without more information about the transmural source of the sample 108, 117, 
125. 
Two additional projects have used animal tissues to assess potential transmural 
changes in Ca2+ sensitivity in pigs 47 and rats 46. Both studies showed that Ca2+ 
sensitivity increased from the epicardium to the endocardium in healthy hearts, 
similar to the present work. The rodent study also showed that transmural 
variation in Ca2+ sensitivity was eliminated 46 14 weeks after a myocardial 
infarction which is, again, broadly consistent with the current data from failing 
hearts (Figure 4.4). 
Modulation of Ca2+ sensitivity is complex. The current data suggest that one 
molecular mechanism that may modulate the transmural variation in pCa50 in 
non-failing hearts (Figure 4.4) is phosphorylation of cMyBP-C. Post-hoc tests 
showed that Ser302 phosphorylation in non-failing epicardial samples was 
greater than in non-failing mid-myocardial tissue (p=0.047, Figure 4.15A-B) 
Regression analysis showed that pCa50 values for the non-failing preparations 
were negatively correlated with both total cMyBP-C phosphorylation (p=0.002, 
Figure 4.20A) and Ser302 phosphorylation (p=0.045, Figure 4.20B). The former 
finding reinforces data from a previous study using myocardial samples from 
unspecified regions of human hearts 120 but the new link between 
phosphorylation of cMyBP-C at Ser302 and pCa50 is a novel finding. 
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Other groups have shown that cTnI phosphorylation can also influence Ca2+ 
sensitivity 118, 126. In this study, site-specific cTnI phosphorylation was reduced in 
heart failure samples at Ser23/24 (Figure 4.12B, p=0.012) but there was not a 
significant relationship between this parameter and pCa50 (r=0.034, p=0.850, 
data not shown). Total cTnI phosphorylation was not correlated with pCa50 either 
(r=-0.011, p=0.942, data not shown). However, site-specific phosphorylation of 
cTnI at Ser 23/24 correlated with cMyBP-C (Figure 4.21). cTnI undergoes many 
complex posttranslational modifications – the human cardiac isoform has 14 
phosphorylation sites 127. It is therefore possible that more detailed analysis 
might have revealed significant relationships. For example, phosphorylation of 
cTnI at Ser149 has been shown to increase Ca2+ sensitivity 128 but this 
modification was not investigated in this study. 
Another posttranslational modification that has been linked to changes in 
myocardial Ca2+ sensitivity is phosphorylation of MLC-2. Davis et al. 100 have 
reported that MLC-2 phosphorylation is greater in sub-epicardial than in sub-
endocardial tissue. Data from rat trabeculae 129 suggest that this phosphorylation 
gradient would increase Ca2+ sensitivity in epicardial tissue. However, the 
situation is complex, because van der Velden et al. 109 have shown that 
increased phosphorylation of MLC-2 decreases pCa50 values. Unfortunately, 
MLC-2 phosphorylation was not studied in this work. 
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4.3.4. Proteins that influence power output 
The transmural heterogeneity of myocardial power output and its modification by 
heart failure are the key findings of this study. However, it was not possible to 
identify a specific sarcomeric protein that explains the functional changes. 
The content of intact cTnI (Figure 4.11A) was reduced in biospecimens from 
failing hearts (p=0.021) but did not exhibit transmural variation (interaction term, 
p=0.853). Further analysis of these data showed that cTnI content was lower in 
patients with ischemic heart failure than in patients with non ischemic disease 
(p=0.029, Figure 4.22). This is consistent with a study by McDonough et al. which 
showed that cTnI is degraded in human hearts after ischemic injury 130. 
Degradation of cTnI inhibits contractility in mice 131 and the current data show 
that this mechanism probably impacts human myocardial function too. Power 
output (Figure 4.16A) and force (Table 4.7) both correlated with the relative cTnI 
content, indicating that proteolyis of cTnI may be another impact factor in human 
disease 131. 
Desmin, a structural protein that links myofibrils at Z-disks and maybe involved in 
force transmission 132, has been proposed as a potential biomarker for heart 
failure 133, 134. Pawlak et al. 134 had previously shown that desmin content is 
increased in endocardial biopsies from patients with heart failure and this result 
was confirmed in the present work (Figure 4.13A). There was also a decrease in 
the total phosphorylation of desmin in samples from failing hearts (Figure 4.13B) 
135. Although desmin content did not vary with transmural region (p=0.514), the 
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regression tests summarized in Figure 4.16B-C show that changes to the content 
and phosphorylation of this protein may modulate power output. 
Similarly, power increased linearly with MLC-1 content (p=0.034, Figure 4.16D) 
and decreased with MLC-1’s relative phosphorylation (p=0.006, Figure 4.16E). 
Since MLC-1 binds to the lever arm of the myosin head near the convertor 
domain, it is ideally positioned to influence force generation and/or kinetics. For 
example, previous work by Morano et al. 136 and new data in Table S7 show that 
MLC-1 phosphorylation decreases Vmax. There are only a few studies describing 
MLC-1 phosphorylation but phosphorylation sites corresponding to the human 
isoform are known as Thr64 and Ser194/195 137. Intriguingly, phosphorylation of 
MLC-1 has recently been shown to increase the molecule’s degradation by 
matrix metalloproteinase-2 138-140. When combined with these previous findings, 
the new data presented in this manuscript show that MLC-1 modulates power 
output in human myocardium, and that loss of MLC-1 (perhaps following its 
phosphorylation) decreases contractility. To our knowledge, this is the first study 
to identify significant correlations between the power output of human 
myocardium and modifications to the content and phosphorylation status of cTnI, 
desmin and MLC-1. 
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4.3.5. Proteins that influence rate of tension redevelopment 
The rate at which the myosin cross bridges generate force is an in vitro measure 
of the rate at which the ventricles generate pressure during systole. This property 
did not change significantly with heart failure status in our study (Figure 4.7). 
In animal models of cardiac disease and aging ktr has been shown to modulate 
with a shift in the isoform content of MHC. For example, F344 rats express more 
β-MHC with age 15 and this shift in the relative content of MHC isoform has been 
shown to significantly correlate with slowed ktr 68, 106, 141. In humans a shift in 
MHC isoform content in less likely to modulate ktr because ~95% of MHC 
expressed in the left ventricles is β-MHC and does not change much with heart 
failure 142. In our study the relative expression of α and β-MHC content was 
unaffected by heart failure. None of the ventricular samples contained detectable 
amounts of the α isoform although paired α and β myosin heavy chain bands 
were clearly resolved in atrial samples used as positive controls (Figure 4.23). 
These results suggested that there are other proteins that modulate ktr in human 
myocardium. In our study we found cMyBP-C, MLC-2 and MLC-1, three proteins 
that were structurally bound to MHC to be significantly correlated with ktr (4.17). 
Previous studies have shown that ktr increases significantly in cMyBP-C knockout 
mice 143, 144 and by phosphorylation of cMyBP-C through PKA incubation at 
submaximal concentration of calcium 145. Both of these findings suggest that the 
relative content and phosphorylation of cMyBP-C can modulate ktr, similar to our 
study (Figure 4.17A and B).  
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Similarly MLC-1 and MLC-2 both are located on the lever arm of the myosin head 
and are known to affect cross bridge kinetics 146-148. In our study ktr increased 
significantly with the contents of both these proteins (Figure 4.17C and E). 
Another important result was that cMyBP-C was highly correlated with MLC-1 
and MLC-2 content (p<0.001, Figure 4.24), which suggested that the effect of 
each of these thick filament protein may be masked by the other (called 
multicolinearity in statistical terms). Therefore an animal model maybe useful to 
investigate the effect of each of these proteins on ktr. 
4.3.6. Conclusion 
This is the first study to show that (1) the contractile properties of non-failing 
human hearts exhibit transmural variation, and that (2) heart failure alters the 
transmural pattern as well as depressing overall function.  
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Table 4.1. Content of selected sarcomeric proteins in non-failing and failing 
tissue 
    cMyBP-C cTnT Actinin 
     
Non-failing 
Epi 1.17±0.18 1.63±0.47 1.07±0.17 
Mid 1.03±0.10 1.21±0.31 0.94±0.09 
Endo 1.11±0.10 1.25±0.37 0.92±0.07 
          
Heart failure 
Epi 1.03±0.07 1.10±0.29 1.06±0.07 
Mid 1.09±0.07 1.20±0.31 1.14±0.10 
Endo 0.88±0.10 1.01±0.34 0.99±0.30 
          
Main statistical 
effects and 
interaction 
(p values) 
Condition 0.388 0.616 0.439 
Region 0.448 0.655 0.452 
Condition *Region 0.231 0.455 0.537 
Protein contents are expressed in arbitrary units and were calculated by 
normalizing to data obtained for each protein from a non-failing sub-
epicardial sample that was loaded onto every gel as a control. 
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Table 4.2. Content of myosin light chain proteins in non-failing and failing 
tissue. 
    MLC-1 MLC-2 
    
Non-failing 
Epi 1.24±0.14 1.22±0.22 
Mid 1.09±0.08 1.11±0.10 
Endo 1.16±0.11 1.22±0.22 
        
Heart failure 
Epi 1.12±0.10 1.15±0.11 
Mid 1.18±0.09 1.15±0.10 
Endo 0.95±0.14 1.01±0.15 
        
Main statistical 
effects and 
interaction 
(p values) 
Condition 0.589 0.702 
Region 0.395 0.725 
Condition *Region 0.243 0.639 
Protein contents are expressed in arbitrary units and were 
calculated by normalizing to data obtained for each protein from a 
non-failing sub-epicardial sample that was loaded onto every gel 
as a control. 
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Table 4.3. Content of Myosin Heavy Chain (MHC) and Actin in non-failing and 
failing tissue. 
   MHC Actin 
    
Non-failing 
Epi 0.79±0.08 0.71±0.10 
Mid 0.71±0.05 0.71±0.04 
Endo 0.78±0.06 0.71±0.04 
       
Heart failure 
Epi 0.74±0.03 0.66±0.02 
Mid 0.69±0.04 0.58±0.03 
Endo 0.71±0.07 0.62±0.07 
       
Main statistical 
effects and 
interaction 
(p values) 
Condition 0.345 0.092 
Region 0.534 0.764 
Condition*Region 0.920 0.772 
Protein contents are expressed in arbitrary units and were calculated by 
normalizing to data obtained for each protein from a non-failing sub-epicardial 
sample that was loaded onto every gel as a control, and corrected for the initial 
weight of the original tissue sample. 
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Table 4.4. Phosphorylation of selected sarcomeric proteins in non-failing 
and failing tissue. 
 
 
Phospho 
cMyBP-C 
Phospho 
cTnT 
Phospho 
MLC-1 
     
Non-failing 
Epi 1.03±0.09 1.24±0.33 1.02±0.14 
Mid 1.05±0.1 1.59±0.30 1.26±0.18 
Endo 0.95±0.1 1.77±0.47 1.17±.0.11 
     
Heart failure 
Epi 0.79±0.05 1.91±0.46 1.34±0.19 
Mid 0.77±0.06 1.68±0.39 1.34±0.26 
Endo 0.86±0.16 2.16±0.49 1.52±0.24 
     
Main statistical 
effects and 
interaction 
(p values) 
Condition 0.094 0.53 0.367 
Region 0.999 0.237 0.345 
Condition *Region 0.554 0.484 0.457 
Phosphorylation levels are expressed in arbitrary units and were calculated 
by normalizing to data obtained for each protein from a non-failing sub-
epicardial sample that was loaded onto every gel as a control. 
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Table 4.5. Site-specific phosphorylation of cMyBP-C at Ser273 and Ser282 in 
non-failing and failing tissue. 
 
 
PSer273 
cMyBP-C 
PSer282 
cMyBP-C 
    
Non-failing 
Epi 1.38±0.28 1.01±0.17 
Mid 1.39±0.35 1.01±0.14 
Endo 1.38±0.35 1.01±0.21 
    
Heart failure 
Epi 1.31±0.27 0.97±0.08 
Mid 1.35±0.27 0.94±0.07 
Endo 1.03±0.16 0.97±0.08 
    
Main statistical 
effects and 
interaction 
(p values) 
Condition 0.685 0.76 
Region 0.406 0.96 
Condition *Region 0.428 0.900 
Phosphorylation levels are expressed in arbitrary units and 
were calculated by normalizing to data obtained for each 
protein from a non-failing sub-epicardial sample that was 
loaded onto every gel as a control. 
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Table 4.6. Statistically significant linear relationships between ktr and 
biochemical data. 
Biochemical variable r p value 
Myosin 0.402 0.006 
Actin 0.367 0.012 
Actinin 0.290 0.045 
MLC-2 0.535 <0.001 
Phospho Desmin 0.425 0.031 
Phospho cTnI 0.298 0.039 
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Table 4.7. Statistically significant linear relationships between functional and 
biochemical data. 
Biochemical variable Functional parameter r p value 
cTnI Maximum force 0.291 0.045 
Actin Maximum force 0.027 0.034 
Phospho cMyBP-C pCa50 -0.450 0.001 
Phospho MLC-1 Vmax -0.287 0.048 
PSer273 cMyBP-C Vmax 0.396 0.023 
PSer282 cMyBP-C Vmax 0.396 0.023 
PSer23/24-cTnI Passive stiffness 0.390 0.025 
PSer23/24-cTnI Passive force 0.390 0.006 
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Figure 4.1. Mechanical records. 
Superposed force and length records obtained during force-velocity experiments 
performed with a representative preparation isolated from the mid-myocardium of 
A) a non-failing heart and B) a failing heart (Force-velocity and force-power 
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curves from these records are shown in Figure (4.2). The left hand shows the x-
axis time-scale for the complete experiments. The right hand side shows the 
expanded x-axis time-scale for the same experiments. 
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Figure 4.2. Transmural heterogeneity of power output is reduced in heart 
failure. 
A) Representative force-velocity and force-power curves measured using 
individual preparations from the sub-epicardial, mid-myocardial, and sub-
endocardial regions of the left ventricle of one non-failing (NF, left) and one 
failing (HF, right) heart. B) Symbols show the mean of the power outputs 
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measured from 2 or 3 preparations from each region for each heart. In this figure, 
and in all similar panels, thin lines join data points from the same heart. Thick 
bars show the mean data for the region. The text above the plot shows p values 
for the main statistical effects. Significant differences between regions, tested 
separately for non-failing and failing hearts, are listed in the inset box. Significant 
differences due to heart failure, tested separately for each region, are indicated 
by asterisks (* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001). 
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Figure 4.3. Transmural heterogeneity is reduced in heart failure with 
isometric force but not with maximum shortening velocity.  
A) Symbols show the mean of the maximum isometric forces measured from 2 or 
3 preparations from each region for each heart. B) Symbols show the mean of 
the maximum shortening velocities measured from 2 or 3 preparations from each 
region for each heart. 
93 
 
 
 
Figure 4.4. Transmural variation in Ca2+ sensitivity is disrupted in heart 
failure. 
A) Mean values of normalized isometric tension plotted against pCa 
(= -log10[Ca2+]) for preparations from the three transmural regions of non-failing 
(left) and failing (right) hearts. Circles, squares, and triangles show data for sub-
epicardial, mid-myocardial, and sub-endocardial preparations respectively. B) 
Symbols show the mean of the pCa50 values measured using 2 or 3 preparations 
from each region for each heart.  
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Figure 4.5 Relative short-range stiffness depends on heart failure status. 
A) Short-range stiffness and B) relative short-range force measured in pCa 4.5 
solution. Stiffness values are expressed as Young’s Moduli and were calculated 
by fitting regression lines to the force responses measured during 4% length 
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changes imposed at a speed of 0.12 l0 s-1. In both plots, symbols show the mean 
data value measured from 2 or 3 preparations from each region for each heart. 
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Figure 4.6. Rate of tension redevelopment dependence on the 
concentration of calcium. 
ktr plotted as a function of relative isometric tension for A) non-failing samples 
and B) failing samples. Symbols show the mean of the ktr values measured using 
2 or 3 preparations from each region for each heart in different pCa solutions 
plotted against relative isometric tension. The relative tension in pCa 4.5 solution 
was defined as 1. 
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Figure 4.7 Rate of tension redevelopment (ktr) does not depend on heart 
failure status. 
Symbols show the mean of the ktr measured from 2 or 3 preparations from each 
region for each heart in A) pCa 4.5 and B) pCa 5.7. 
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Figure 4.8. Representative images of myocardial sections from one non-
failing and one failing heart stained with picrosirius red. 
Red staining indicates collagen. Yellow staining shows non-fibrotic tissue. 
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Figure 4.9. Collagen content is elevated in heart failure and is greatest in 
mid-myocardial tissue. 
A) Symbols show the mean collagen to tissue ratio measured from 1-6 sections 
from each region for each heart. B) Actin and C) myosin contents (determined by 
Lowry protein assays and gel electrophoresis) plotted against the collagen to 
tissue ratios from panel B. A.U. stands for arbitrary units. Symbols follow the 
same shape and color conventions as in panel B. The plots also show the best-fit 
straight lines determined by linear regression and the corresponding p and r 
values.  
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Figure 4.10. Broadrange gel stained for phosphorylated and total 
sarcomeric proteins. 
Two images of a single representative gel stained with Pro-Q Diamond (left) and 
SYPRO Ruby (right). The Pro-Q Diamond stain is more sensitive to 
phosphoproteins while SYPRO Ruby indicates total protein content.  
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Figure 4.11. cTnI content decreases with heart failure and phospho cTnI 
depends on transmural region. 
A) Symbols show the relative content of cTnI for each region for each heart using 
SYPRO Ruby stain for total protein. B) Symbols show the mean Phospho cTnI 
measured for each region for each heart using Pro-Q Diamond (phospho-
sensitive stain). A.U. stands for arbitrary units. 
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Figure 4.12. PSer23/24 cTnI is reduced in heart failure. 
A) Representative immunoblots showing total cTnI and PSer23/24 cTnI for non-
failing and failing hearts. B) Symbols show the mean PSer23/24 cTnI measured 
for each region for each heart. A.U. stands for arbitrary units 
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Figure 4.13. Desmin content increases and its phosphorylation decreases 
with heart failure 
A) Symbols show the relative content of desmin for each region for each heart 
using SYPRO Ruby stain for total protein. B) Symbols show the mean phospho 
desmin measured for each region for each heart using Pro-Q Diamond 
(phosphor-sensitive stain). A.U. stands for arbitrary units.  
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Figure 4.14. The relative content of the N2BA isoform of titin is increased in 
heart failure. 
A) Titin gels stained with Pro-Q Diamond (left) and SYPRO Ruby (right). The 
figure shows lanes collated from several gels. The Pro-Q Diamond stain is 
sensitive to phosphoproteins while SYPRO Ruby indicates total protein content. 
B) Symbols show the relative content of the N2BA isoform for each region for 
each heart. A.U. stands for arbitrary units. C) As for panel B but showing the 
relative content of phosphorylated N2BA protein. 
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Figure 4.15. PSer302 cMyBP-C depends on transmural region. 
A) Representative immunoblots showing total cMyBP-C and PSer302 cMyBP-C 
for non-failing and failing hearts. B) Symbols show the mean PSer302 cMyBP-C 
measured for each region for each heart. A.U. stands for arbitrary units. 
  
107 
 
 
 
Figure 4.16. Statistically significant relationships between maximum power 
and biochemical data. 
Each panel shows the relationship between maximum power and a selected 
biochemical property (for example, actin content). The y coordinate of each 
symbol indicates the mean value of maximum power measured from 2 or 3 
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preparations from each region for each heart. The x coordinate of each symbol 
shows the result of the biochemical assay performed using the matching sample. 
The plots also show the best-fit straight lines determined by linear regression and 
the corresponding p and r values. Table S4 provides r and p values for additional 
relationships that had p values less than 0.05. 
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Figure 4.17. Statistically significant relationships between rate of tension 
redevelopment and biochemical data. 
Each panel shows the relationship between ktr and a selected biochemical 
property (for example, actin content). The y coordinate of each symbol indicates 
the mean value of ktr measured from 2 or 3 preparations from each region for 
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each heart. The x coordinate of each symbol shows the result of the biochemical 
assay performed using the matching sample. The plots also show the best-fit 
straight lines determined by linear regression and the corresponding p and r 
values. Table 6 provides r and p values for additional relationships that had p 
values less than 0.05. 
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Figure 4.18. Contractile function is reduced with decrease in actin content. 
A) Maximum Force and B) Maximum Power plotted against the actin content. C) 
Maximum Force and D) Maximum Power plotted against the myosin content. 
Protein content was determined by Lowry protein assays and corrected for initial 
weight of the tissue (Table S3 and gel electrophoresis Figure 13A). A.U. stands 
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for arbitrary units. The plots show the best-fit straight lines determined by linear 
regression and the corresponding p and r values. 
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Figure 4.19. Passive force and passive stiffness do not depend on heart 
failure status. 
A) Passive force and B) passive stiffness measured in pCa 9.0 solution. In both 
plots, symbols show the mean data value measured from 2 or 3 preparations 
from each region for each heart.  
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Figure 4.20. Ca2+ sensitivity of non-failing samples depended on the 
phosphorylation of cMyBP-C. 
Ca2+ sensitivity of non-failing samples correlated significantly with A) total 
phosphorylation of cMyBP-C and B) site-specific phosphorylation of cMyBP-C at 
Ser302. A.U. stands for arbitrary units. The plots show the best-fit straight lines 
determined by linear regression and the corresponding p and r values. 
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Figure 4.21. Site-specific phosphorylation of cTnI at Ser23/24 correlated 
with phosphorylation of cMyBP-C. 
A) Total phosphorylation and B) site-specific phosphorylation of cTnI at Ser23/24 
correlations with total phosphorylation of cMyBP-C. A.U. stands for arbitrary 
units. The plots show the best-fit straight lines determined by linear regression 
and the corresponding p and r values. 
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Figure 4.22. cTnI content is reduced in ischemic heart failure. 
Symbols show the mean cTnI content measured for each region for failing hearts 
with ischemic disease (left) and non-ischemic disease (right). 
  
117 
 
 
 
Figure 4.23. MHC isoforms. 
β-MHC bands seen in the non-failing and failing samples from the transmural 
regions. The human atrial samples have both the α- and β-MHC resolved. 
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Figure 4.24. cMyBP-C strongly correlated with both MLC-1 and MLC-2. 
Significant correlations between cMyBP-C and A) MLC-1 and B) MLC-2. 
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Chapter 5. Discussion 
5.1. Overall Conclusions 
The heart can fail as pump due to decreased contractility or diminished 
ventricular relaxation. One or both of these impairments can get progressively 
worse and lead to irreversible heart failure. In this dissertation, we sought to 
identify transmural cellular level contractile mechanisms that are modified in the 
left ventricle just prior to the onset of heart failure and in end-stage heart failure. 
This dissertation demonstrates that normal left ventricles exhibit transmural 
heterogeneity in cellular level contractile properties and that with aging and heart 
failure there are region-specific changes in cellular level contractile mechanisms. 
The aging F344 rat study detailed in Chapter 3 revealed that the 22-month old 
animals exhibited a region-specific decrease in phosphorylation of cTnI in the 
sub-epicardial samples when compared to the mid-myocardial and sub-
endocardial samples of the same age. This molecular modification may 
contribute to the slowed relaxation of sub-epicardial myocytes in the 22-month 
old animals. We were thus able to identify a molecular level modification, which 
potentially contributes to diastolic dysfunction before the onset of aging 
associated heart failure. 
The human heart failure study detailed in Chapter 4 revealed that the contractile 
properties of human hearts exhibit transmural variation in non-failing organs, and 
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that heart failure alters the transmural pattern as well as depressing myocardial 
function. These new results show that contractile properties are heterogenous in 
non-failing left ventricles and that there are region-specific modifications in 
contractile properties with heart failure. These new results help to explain why in 
vivo shortening of the middle transmural region is a better predictor of 
cardiovascular death than traditional global measures of ventricular function. 
5.2. Limitations of the studies in this dissertation 
5.2.1. Use of rodent model 
Even though rodent models are very useful in understanding mechanisms of 
cardiac dysfunction they have some disadvantages like differential expression of 
ion channel, Ca2+ handling proteins and sarcomeric proteins compared to 
humans 68, 149, 150. In Chapter 3, we discussed that 6-month old rodents express 
~70 % of α-MHC (Figure 3.5). With age 65 and disease 151 the rodents switch to a 
greater proportion of the β-MHC isoform. Furthermore, the increase in the 
proportion of β-MHC isoform slows cross bridge kinetics and can affect both 
contraction 152 and relaxation properties 68. Even though there is a functional 
effect of the β-MHC isoform shift with aging and disease in rodents, this may not 
be the case in humans. Non-failing human hearts already express ~ 90-100% β-
MHC isoform 116, 142 (Figure 4.23) and therefore the shift in isoform if any will be 
very small with human heart failure 123. This means that there are other 
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mechanisms that influence kinetics in humans and it would be hard to tease out 
these mechanisms using animal models because of the dominating effect of β-
MHC isoform shift on kinetics. 
5.2.1.1. Biochemical analysis 
One of the limitations of the aging F344 rat study was that the n=3 animals in 
each age group for the biochemical analysis. This meant that the study may have 
been under powered. Future studies may require increase in the number of 
animals. 
5.2.2. Use of human tissue 
Humans are genetically different from each other and come from different 
environments. However, it is important to note that the use of human tissue 
provides data that is more clinically relevant than some animal studies and is 
thus arguably of more translational relevance. 
We had logistical difficulty in obtaining the human tissue samples that were age 
and gender matched to the donors and patients (Table 2.2). As discussed in 
section 2.1.2.2, the mean age of the patients with heart failure was 49 (range 20 
to 65) while that of the organ donors was 35 (range 18 to 59). Females donated 
20% of the failing hearts and 50% of the non-failing organs. We performed 
regression analyses and showed that the key contractile properties reported in 
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this work did not vary with age (Figure 5.1). Furthermore, we showed that there 
was no significant interaction between gender and condition in our study 
(Figure  5.2) for the key contractile properties suggesting that heart failure was 
not gender dependent. 
We also investigated the effect of β blocker on heart failure patients because β-
adrenergic stimulation activates an important signaling pathway that can regulate 
various contractile proteins 63, 110, 153. We did not find any significant difference in 
the key contractile properties measured and the effect of β-blocker (Figure 5.3). 
It is possible that ischemic and non ischemic heart failure produce distinct 
changes in contractile function (Tables 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9 
and 5.10 and Figures 4.22 and 5.4). Due to the small sample size (n=5 in both 
heart failure groups), tests comparing ischemic and non-ischemic samples had 
limited statistical power. The results from Tables 5.9 and 5.10 could be 
interpreted as suggesting that failing non ischemic tissue has worse contractile 
function than failing ischemic tissue. It would be interesting to follow up on these 
results in future work using larger numbers of hearts. 
All of the organ donors in this study had been treated in Intensive Care Units 
before the determination of brain death and some had comorbidities such as 
diabetes and/or hypertension. Therefore, it is unclear whether the non-failing 
hearts are truly representative of healthy organs. However, none of the donors 
had a prior history of ventricular dysfunction and the hearts used in this work are 
the best controls that are available. 
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5.2.2.1. Permeabilized samples 
We performed functional measurements using chemically permeabilized 
multicellular preparations. These biospecimens were optimal for testing 
myofibrillar-level function and for investigating the effects of the extracellular 
matrix on passive mechanical properties. However, additional experiments using 
enzymatically isolated cells that are still electrically excitable could also have 
investigated potential transmural variation in calcium handling (similar to the 
functional experiments done in Chapter 3 65) 154 and mitochondrial function 155. 
These measurements cannot be performed once the membranes have been 
permeabilized. 
5.3. Linking in vitro mechanics to in vivo function 
5.3.1. Pressure-volume relationship 
The pressure-volume loop (PV) gives in vivo information about left ventricular 
performance during a single cardiac cycle. The PV loop can be divided into 4 
phases (Figure 5.5A). In phase “a” (diastole) the mitral valve opens and 
ventricular filling occurs. In phase “b” (systole) the mitral valve closes and 
isovolumic contraction occurs where the left ventricular pressure rises and the 
volume remains the same. In phase “c” (systole) the aortic valve opens after the 
left ventricular pressure exceeds the aortic pressure, which then leads to 
ejection. During ejection the heart has to perform external work against an 
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afterload. In phase “d” (diastole), the aortic valve closes after the ventricular 
pressure becomes lower than the aortic pressure and isovolumic relaxation 
occurs. The ventricular pressure declines further and the ventricle begins to relax 
without a change in volume. PV loops can therefore yield information about the 
work done by the ventricle. Detrimental changes to any of these 4-phases can 
indicate cardiac dysfunction. 
5.3.2. Permeabilized preparations-in vitro mechanics 
The cellular level contractile properties investigated in this dissertation gives an 
in vitro index of systolic and diastolic function. In the human heart failure study 
detailed in Chapter 4, we measured active and passive mechanical properties of 
multicellular preparations, which were representative of the myocytes linked with 
the connective tissue in the left ventricle. Figure 5.5 summarize some of the in 
vitro parameters investigated in this study that we can compare to the different 
phases of the PV loop. For example, the in vitro measure of force and power 
gives us information about phase “c” (ejection) of the PV loop. In our study, there 
was an ~20% decrease in power in heart failure samples (Figure 4.2) and this in 
vitro measure indicates systolic dysfunction at the cellular level. Similarly, we did 
not see a significant difference in the rate of tension redevelopment in failing 
hearts (Figure 4.7) which in our study may potentially be an index of rate of 
pressure development (dp/dt). 
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It should be noted that the extrapolation of the in vitro mechanical properties to 
the PV loop is simplistic because the PV loop is indicative of global left 
ventricular function. However, the in vitro measurements are representative of 
the mechanical behavior of the sarcomeres and connective tissue that contribute 
to the various phases of the PV loop and can therefore be extremely useful to 
identify molecular and cellular level modifications. 
5.4. Sarcomere level therapies for heart failure 
Modifications to sarcomeric proteins can lead to pump dysfunction 63. In this 
dissertation we reported posttranslational modifications to sarcomeric proteins, 
isoform switch and decrease in the relative content of sarcomeric proteins in 
aging (Chapter 3) and in heart failure (Chapter 4).  
One of the major modifications that can regulate sarcomere function is 
phosphorylation of sarcomeric proteins like cTnI, cMyBP-C and titin. Studies 
have shown that PKA, PKC and PKG are the main kinases that phosphorylate 
these proteins 63, 126, 156. Changes to the phosphorylation level of sarcomeric 
proteins can alter contractile function. For example, in heart failure, there is a 
decrease in β2 stimulations either due to desensitization of the β2 receptors or 
decrease in the content of the receptors themselves 157. Activation of the β2-
adrenergic receptor signaling leads to an increase in cAMP, which in turn 
activates PKA. PKA can then phosphorylate sarcomeric proteins including cTnI, 
cMyBP-C and Titin 158. In the aging F344 rat study we saw a decrease in cTnI 
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phosphorylation in the sub-epicardial cells of 22-month old F344 rats (Figure 3.7) 
and in the human heart failure study we saw a site-specific decrease in 
phosphorylation of cTnI at Ser 23/24 in failing hearts (Figure 4.12). In the aging 
F344 rat study phosphorylation of cTnI was linked to slowed relaxation and in the 
human heart failure study there was a significant novel correlation between site-
specific phosphorylation of cTnI at Ser 23/24 and passive stiffness (Table 4.7). 
These results from both rodent and human studies (Chapter 3 and 4) make 
phosphorylated cTnI a potential contributor to relaxation and therefore a 
therapeutic target for diastolic dysfunction. 
Sarcomere-level interventions could potentially be effective treatment for heart 
failure. For example, a cardiac specific myosin activator molecule 159 is in phase 
II clinical trials and is being evaluated for acute and chronic systolic heart failure. 
Its mechanism of action allows the myosin cross bridges to strongly bind to actin 
and stay bound for a longer duration 160. In the human heart failure study for 
example, we not only saw a significant decrease in cTnI content in human heart 
failure (Figure 4.11) we also saw a significant correlation between power and 
relative cTnI content (Figure 4.16A) which is a potential sarcomeric protein that 
can be targeted to improve cardiac function. 
5.5. Importance of transmural heterogeneity in the ventricular wall 
Anatomical location is sometimes ignored when studying the left ventricle 
because it is assumed that it is a homogenous structure. However, in Chapter 1 
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(section 1.1), we discussed that the ventricular wall is made up “layers” of muscle 
with changing fiber angles 1-4, 6. There are known transmural differences in action 
potential morphologies in human and animal hearts 42-44 and few studies in 
animals have shown differences in contractile properties 46, 47, 64, 101. Our study, 
for the first time showed differences in contractile properties across the 
ventricular wall in non-failing and failing human myocardium (Chapter 4) and a 
region-specific molecular modification in aging F344 rats (Chapter 3). 
5.5.1. The mid-myocardium in the failing human heart 
Ingels, 1997 10, laid down several working hypothesis to explain the coupling 
between the myocardial fiber architecture and left ventricular function. He utilized 
LaPlace’s law (P=Tw/r where T is wall tension; w is wall thickness and r is radius 
of the cavity) and proposed that the mid-myocardial circumferential fibers are 
optimal to develop pressure because they have a minimum radius of curvature 
when compared to the spiral sub-endocardial fibers which are better suited to 
maximize ejection fraction 10. In the human heart failures study we saw a 
significant decrease in force and power and increased fibrosis in the mid-
myocardial samples of the failing hearts (Figure 4.2, 4.3A, 4.8 and 4.9). These 
region-specific changes could contribute to the decrease in global ventricular 
function in patients in end-stage heart failure because the mid-myocardial 
circumferential fibers necessary to generate the required pressure are 
dysfunctional. 
128 
 
 
5.5.2. The mid-myocardial region of non-failing human hearts 
The mid-myocardial samples from the non-failing human hearts exhibited 
increase in power and force (4.2 and 4.3A) compared to the sub-epicardial and 
sub-endocardial samples. There are two potential reasons as to why the 
myocytes from the mid-myocardial region have different contractile 
properties, 1)  the environment that these myocytes are located in in vivo make 
them different and/or 2) myocytes from the mid-myocardial region are specialized 
myocytes. 
5.5.2.1. Mechanosensitive pathways 
The mid-myocardial fibers are arranged circumferentially in the left ventricle while 
the sub-epicardial and the sub-endocardial fibers are more longitudinally 
arranged 5. This means that the myocytes in the mid-myocardial region 
potentially undergo different mechanical stress and strain stimuli than the 
myocytes in the sub-epicardial and sub-endocardial regions. Studies have shown 
that longitudinal vs. tranverse stretch can bring about different anistropic 
(dependent on direction) changes in myocytes and lead to differential 
upregulation of sarcomeric proteins 161-163.  The major signal transduction 
pathways that are activated by mechanical stimuli are mitogen-activated protein 
kinase (MAPK) pathway, the Janus-associates kinases/signal transducers and 
activators of transcription (JAK/STAT) 164 and/or the Ca2+/calmodulin-dependent 
phosphatase calcineurin 165. Particularly, z-disk proteins and titin have been 
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implicated in being able to sense changes in cell stress and strain, which then 
leads to transcriptional regulation 166, 167. 
Further studies need to be done in order to understand the role of these 
pathways in non-failing human hearts. 
5.5.2.2. M cells 
There is some evidence of the existence of specialized population of myocytes in 
the mid-myocardium known as M cells. These cells have been extensively 
studied due to their distinct electrophysiological properties and are described to 
be a hybrid of purkinje and ventricular cells 168. Specifically, M cells have a 
characteristically prolonged action potential duration when compared to the sub-
epicardial and sub-endocardial myocytes 42, 168 and are present in different 
species including humans 169, 170 41. A recent study demonstrated that M cells 
were present in island like cluster in non-failing human hearts but were not found 
in the failing human heart 42. The M cells may have distinct electrophysiological 
properties but further studies need to be done to investigate if they also have 
distinct contractile properties.  
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5.6. Application of this work 
The findings from these studies have broader implication in three major 
cardiovascular fields that strive for patient-specific treatments- mainly cardiac 
imaging, ventricular finite element modeling and stem cell research.  
5.6.1. Imaging studies 
Both the aging F344 rat study and the human heart failure study revealed region-
specific modifications in aging and failing left ventricles. The aging F344 rat study 
made use of imaging tools and demonstrated that ventricular torsion changes 
with age 65 and previous clinical studies have shown that shortening of the mid-
myocardial region in a better predictor of cardiovascular outcomes than 
shortening of the endocardial region and ejection fraction 26-30. All of these 
studies point out that global measures of ventricular function (ejection fraction) 
may not be sufficient for patient prognosis. With the increased use of MRI 
(magnetic resonance imaging) it will become more feasible to isolate region-
specific changes that occur in dysfunctional myocardium 171. 
5.6.2. Ventricular modeling 
Computational models of the human hearts use in vivo imaging data to make 
predictions of myocardial contractility in patients with damaged myocardium 172. 
But it has become more evident that multiscale modelling maybe more accurate 
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in predicting ventricular function because it takes into account cellular level 
contractile properties 173. Our data helps to fill this gap as we have transmural 
cellular level contractile data in rodents and humans. 
5.6.3. Stem cell therapies 
In the past several years many advances have been made to utilize stem-cell 
therapy for patients with heart failure. The basic idea is to replace and/or repair 
injured myocardium by delivering stem cells to the heart to improve its function. 
One of the challenges has been to find the best method of stem cell delivery that 
will reach the target 174. There are three main ways to deliver stem cells, 1) 
systemic intravenous infusion, 2) intracoronary infusion, and 3) direct 
intramyocardial injection (for example-during a coronary bypass graft). Each of 
these delivery systems have their own advantages and disadvantages. Even 
though intramyocardial injections are more invasive than other delivery systems, 
studies have shown that the hearts are able to retain stem cells better with this 
approach compared to the other 2 approaches 175-178. 
Our study showed that the mid-myocardial samples from the non-failing hearts 
generate more power and more force than sub-epicardial and sub-endocardial 
samples. Furthermore, the mid-myocardial samples produced the least amount 
of force than sub-epicardial and sub-endocardial samples of the failing hearts 
(Figure 4.2 and 4.3A). This means that delivering stem cells to the mid-
myocardium could be especially beneficial to improve systolic function. 
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Specifically, in patients with non ischemic heart disease who donot have a 
targeted region unlike patients with myocardial infract whose infract region may 
be the target for stem cell delivery. 
5.7. Overall perspective 
Complementary studies in human tissue and animal models needs to be 
performed in order to prevent and cure human heart failure 179. One way to 
approach this is to systematically investigate the molecular level modifications 
that occur with heart failure in human tissue. These modifications should then be 
correlated with functional parameters that strongly predict them. The molecular 
mechanism should then be tested in other systems like transgenic and knockout 
animal models or cell cultures. Integration of all these system is key. In this 
dissertation we have tried to accomplish this method. 
Finally, we have shown that there are contractile transmural heterogeneities 
across the ventricular wall in normal myocardium and there are region-specific 
modifications that occur with aging and heart failure. These cellular level 
modifications can contribute to organ level function and should be taken into 
account. 
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Table 5.1. Functional contractile properties in non ischemic and ischemic 
tissue. 
    
Maximum 
Power 
(μW mg-1) 
Maximum 
Force  
(kN m-2) 
Maximum 
Velocity 
(mL s-1) 
     
Non ischemic 
Epi 0.37±0.04 9.79±1.10 1.05±0.07 
Mid 0.34±0.03 7.69±0.68 1.09±0.09 
Endo 0.31±0.02 9.33±1.09 0.93±0.05 
          
Ischemic 
Epi 0.43±0.03 12.41±0.83 1.00±0.05 
Mid 0.40±0.04 9.90±0.63 1.01±0.07 
Endo 0.36±0.05 9.38±1.09 § 1.06±0.09 
          
Main statistical 
effects and 
interaction 
(p values) 
Condition 0.348 0.228 0.999 
Region 0.045* 0.007** 0.773 
Condition *Region 0.845 0.145 0.334 
Protein contents are expressed in arbitrary units and were calculated by normalizing to 
data obtained for each protein from a non-failing sub-epicardial sample that was loaded 
onto every gel as a control. Difference between main statistical effects and interaction: 
p<0.05= * and p<0.01=**. Different from the sub-epicardial region of the same condition: 
p<0.05= §. 
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Table 5.2. Functional contractile properties in non ischemic and ischemic 
tissue. 
    
Maximum 
Power 
(μW mg-1) 
Maximum 
Force  
(kN m-2) pCa50 
     
Non ischemic 
Epi 0.37±0.04 9.79±1.10 5.68±0.02 
Mid 0.34±0.03 7.69±0.68 5.70±0.02 
Endo 0.31±0.02 9.33±1.09 5.65±0.05 
          
Ischemic 
Epi 0.43±0.03 12.41±0.83 5.69±0.03 
Mid 0.40±0.04 9.90±0.63 5.76±0.05 
Endo 0.36±0.05 9.38±1.09 § 5.72±0.04 
          
Main statistical 
effects and 
interaction 
(p values) 
Condition 0.348 0.228 0.535 
Region 0.045* 0.007** 0.140 
Condition *Region 0.845 0.145 0.286 
Protein contents are expressed in arbitrary units and were calculated by normalizing to 
data obtained for each protein from a non-failing sub-epicardial sample that was loaded 
onto every gel as a control. Difference between main statistical effects and interaction: 
p<0.05= * and p<0.01=**. Different from the sub-epicardial region of the same condition: 
p<0.05= §. 
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Table 5.3. Functional passive properties in non ischemic and ischemic 
tissue. 
    
Passive Force  
(kN m-2) 
Passive Stiffness 
(kN m-2) 
    
Non ischemic 
Epi 0.84±0.08 25.14±4.45 
Mid 0.60±0.07 19.72±3.53 
Endo 0.84±0.11 33.26±6.57 
        
Ischemic 
Epi 1.09±0.13 53.20±12.78 † 
Mid 0.75±0.14 28.88±12.10 
Endo 1.01±0.15 32.54±5.87 
        
Main statistical 
effects and 
interaction (p values) 
Condition 0.080 0.166 
Region 0.030* 0.187 
Condition *Region 0.910 0.209 
Protein contents are expressed in arbitrary units and were calculated by normalizing 
to data obtained for each protein from a non-failing sub-epicardial sample that was 
loaded onto every gel as a control. Difference between main statistical effects and 
interaction: p<0.05= *. Different between the same regions of non ischemic and 
ischemic group: p<0.05= †. 
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Table 5.4. Content of selected sarcomeric proteins in non ischemic and 
ischemic tissue. 
    cMyBP-C cTnT Actinin 
     
Non 
ischemic 
Epi 0.88±0.08 1.09±0.52 0.95±0.10 
Mid 1.1±0.33 1.26±0.58 1.22±0.21 
Endo 1.00±0.13 1.22±0.57 1.08±0.12 
          
Ischemic 
Epi 1.19±0.08 1.11±0.36 1.17±0.08 
Mid 1.08±0.05 1.68±0.39 1.05±0.03 
Endo 0.76±0.15 § 1.00±0.43 0.89±0.15 
          
Main 
statistical 
effects and 
interaction 
(p values) 
Condition 0.904 0.853 0.732 
Region 0.084 0.937 0.402 
Condition *Region 0.025* 0.932 0.146 
Protein contents are expressed in arbitrary units and were calculated by 
normalizing to data obtained for each protein from a non-failing sub-epicardial 
sample that was loaded onto every gel as a control. Difference between main 
statistical effects and interaction: p<0.05= *. Different from the sub-epicardial 
region of the same condition: p<0.05= §. 
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Table 5.5. Content of selected sarcomeric proteins in non ischemic and 
ischemic tissue. 
    MLC-1 MLC-2 
    
Non 
ischemic 
Epi 0.91±0.10 0.96±0.10 
Mid 1.20±0.13 1.21±0.18 
Endo 0.98±.0.16 1.12±0.21 
        
Ischemic 
Epi 1.33±0.10 1.33±0.16 
Mid 1.17±0.14 1.10±0.12 
Endo 0.91±0.24 § 0.90±0.24 
        
Main 
statistical 
effects and 
interaction 
(p values) 
Condition 0.564 0.964 
Region 0.126 0.496 
Condition *Region 0.084 0.096 
Protein contents are expressed in arbitrary units and were 
calculated by normalizing to data obtained for each protein 
from a non-failing sub-epicardial sample that was loaded onto 
every gel as a control. Difference between main statistical 
effects and interaction: p<0.05= *. Different from the sub-
epicardial region of the same condition: p<0.05= §. 
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Table 5.6. Content of Myosin Heavy Chain (MHC) and Actin in non ischemic 
and ischemic tissue. 
   MHC Actin 
    
Non ischemic 
Epi 0.70±0.04 0.64±0.04 
Mid 0.75±0.05 0.61±0.04 
Endo 0.81±0.04 0.66±0.05 
       
Ischemic 
Epi 0.78±0.02 0.68±0.02 
Mid 0.63±0.05 0.54±0.03 
Endo 061±0.13 † 0.58±0.14 
       
Main statistical 
effects and 
interaction 
(p values) 
Condition 0.217 0.608 
Region 0.733 0.515 
Condition*Region 0.124 0.574 
Protein contents are expressed in arbitrary units and were calculated by 
normalizing to data obtained for each protein from a non-failing sub-epicardial 
sample that was loaded onto every gel as a control, and corrected for the initial 
weight of the original tissue sample. Different between the same regions of non 
ischemic and ischemic group: p<0.05= †.  
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Table 5.7. Phosphorylation of selected sarcomeric proteins and residues in 
non ischemic and ischemic tissue. 
 
 
Phospho 
cMyBP-C 
Phospho 
cTnT 
Phospho 
MLC-1 
     
Non 
ischemic 
Epi 0.75±0.10 2.50±0.89 0.91±0.10 
Mid 0.84±0.07 1.93±0.64 1.20±0.13 
Endo 0.73±0.10 1.82±0.47 0.98±0.16 
     
Ischemic 
Epi 0.83±0.03 1.70±0.45 1.33±0.10 
Mid 0.70±0.11 1.43±0.50 1.17±0.14 
Endo 0.10±0.32 2.50±0.89 0.91±0.24 § 
     
Main 
statistical 
effects and 
interaction 
(p values) 
Condition 0.678 0.921 0.564 
Region 0.749 0.370 0.126 
Condition *Region 0.337 0.168 0.084 
Phosphorylation levels are expressed in arbitrary units and were calculated 
by normalizing to data obtained for each protein from a non-failing sub-
epicardial sample that was loaded onto every gel as a control. Difference 
between main statistical effects and interaction: p<0.05= *. Different from 
the mid-myocardial region of the same condition: p<0.05= ‡. Different from 
the sub-epicardial region of the same condition: p<0.05= §. 
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Table 5.8. Phosphorylation of selected sarcomeric proteins and residues in 
non ischemic and ischemic tissue. 
 
 
PSer273 
cMyBP-C 
PSer282 
cMyBP-C 
    
Non 
ischemic 
Epi 0.94±0.28 0.88±0.10 
Mid 1.25±0.44 0.91±0.11 
Endo 0.80±0.17 0.88±0.10 
    
Ischemic 
Epi 1.80±0.49 1.09±0.11 
Mid 1.49±0.35 0.99±0.10 
Endo 1.35±0.21 1.10±0.09 ‡ 
    
Main 
statistical 
effects and 
interaction 
(p values) 
Condition 0.240 0.279 
Region 0.187 0.302 
Condition *Region 0.247 0.043* 
Phosphorylation levels are expressed in arbitrary units and 
were calculated by normalizing to data obtained for each 
protein from a non-failing sub-epicardial sample that was 
loaded onto every gel as a control. Difference between main 
statistical effects and interaction: p<0.05= *. Different from the 
mid-myocardial region of the same condition: p<0.05= ‡. 
Different from the sub-epicardial region of the same condition: 
p<0.05= §. 
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Table 5.9. Functional contractile properties in non-failing and ischemic 
tissue. 
    
Maximum Power 
(μW mg-1) 
Maximum Force  
(kN m-2) pCa50 
     
Non-failing 
Epi 0.46±0.03 10.96±0.74 5.619±0.01 
Mid 0.59±0.06§ 14.30±1.33§ 5.67±0.02 
Endo 0.46±0.04‡ 11.47±0.86‡ 5.69±0.02§ 
          
Ischemic 
Epi 0.43±0.03 12.41±0.83 5.69±0.03 
Mid 0.40±0.04† 9.90±0.63† 5.76±0.05§ 
Endo 0.36±0.05 9.38±1.09§ 5.72±0.04 
          
Main statistical 
effects and 
interaction (p values) 
Condition 0.080 0.230 0.251 
Region 0.057 0.110 0.001 
Condition *Region 0.132 0.004 0.366 
Effect of ischemic status on region: † p<0.05. Different from the sub-epicardial region of the 
same condition: §  p<0.05. Different from the mid-myocardial region of the same condition: ‡ 
p<0.05. 
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Table 5.10. Functional contractile properties in non-failing and non ischemic 
tissue. 
    
Maximum Power 
(μW mg-1) 
Maximum Force  
(kN m-2) pCa50 
     
Non-failing 
Epi 0.46±0.03 10.96±0.74 5.619±0.01 
Mid 0.59±0.06§ 14.30±1.33§ 5.67±0.02 
Endo 0.46±0.04‡ 11.47±0.86‡ 5.69±0.02§ 
          
Non ischemic 
Epi 0.37±0.04 9.79±1.10 5.68±0.02 
Mid 0.34±0.03† 7.69±0.68† 5.70±0.02 
Endo 0.31±0.02† 9.33±1.09 5.65±0.05 
          
Main statistical 
effects and 
interaction (p values) 
Condition 0.009 0.040 0.717 
Region 0.117 0.704 0.096 
Condition *Region 0.091 0.004 0.004 
Effect of non ischemic status on region: † p<0.05. Different from the sub-epicardial region of 
the same condition: §  p<0.05. Different from the mid-myocardial region of the same condition: 
‡ p<0.05. 
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Figure 5.1. No statistically significant relationships between contractile 
properties and age. 
Each panel shows the relationship between a selected functional parameter and 
age. The y coordinate of each symbol indicates the mean value of a functional 
parameter measured from 2 or 3 preparations from each region for each heart. 
The x coordinate of each symbol shows the age of the individual patient/donor. 
The plots also show the best-fit straight lines determined by linear regression and 
the corresponding p and r values. 
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Figure 5.2. Contractile properties did not depend on gender. 
Symbols show the mean of the A) Maximum Power, B) Maximum Force and C) 
pCa50 measured from 4 or 6 preparations from each condition for each heart. 
Thick bars show the mean data for the condition. The text above the plot shows p 
values for the main statistical effects. 
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Figure 5.3. Contractile properties did not depend on β-blocker. 
Symbols show the mean of the A) Maximum Power, B) Maximum Force and C) 
pCa50 measured from 4 or 6 preparations from each heart. Thick bars show the 
mean data with and without β-blocker. The text above the plot shows p values for 
the main statistical effect. 
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Figure 5.4. Collagen content is increased in the mid-myocardium of 
patients with ischemic and non-ischemic disease. 
Symbols show the mean collagen to tissue ratio measured for each region for 
failing hearts with ischemic disease (left) and non-ischemic disease (right). A.U. 
stands for arbitrary units. 
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Figure 5.5. Linking in vitro mechanics to in vivo function. 
A) Schematic pressure-volume loop, B) Raw traces of the 3-stretch protocol, C) 
Force-velocity curve and D) Force-Power curve. The top right panel shows 
variables measured to assess ventricle function. 
Copyright © Premi Haynes 2014  
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Introduction to Elementary Medical Microbiology Lab 
217 (Morehead State University) 
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Spring 2011-Fall 2011 Supervised Alexandria Jarrells (Undergraduate 
Biology Major, University of Kentucky) with human 
biospecimen inventory 
Fall 2011 Supervised Robert N. Hesley (Rotating 1st year 
Graduate Student, University of Kentucky) with 
specialized gel electrophoresis techniques 
Spring 2012 Teaching PGY 207 (Physiology Undergraduate 
discussion course) 
Spring 2012- 2013 Supervised Kristofer E. Nava (Undergraduate Biology 
Major, University of Kentucky) with specialized gel 
electrophoresis techniques 
Fall 2012 Supervised Cheavar A. Blair (Rotating 1st year 
Graduate Student, University of Kentucky) with 
establishing histology protocols for human cardiac 
tissue  
Spring 2013 Supervised Nicholas A. Brown (Rotating 1st year 
Graduate Student, University of Kentucky) with RNA 
extraction and Microarray techniques 
Publications 
1. Shekar P, Campbell K: "This article is interesting because it suggests that, in 
cardiac muscle, cooperativity can be reduced..." Evaluation of: [Kreutziger KL 
et al. Calcium binding kinetics of troponin C strongly modulate cooperative 
activation and tension kinetics in cardiac muscle. J Mol Cell Cardiol. 2010 Oct 
28; doi: 10.1016/j.yjmcc.2010.10.025]. Faculty of 1000, 16 Dec 2010. 
F1000.com/7041956 
2. Campbell SG, Haynes P, Kelsey Snapp W, Nava KE, Campbell KS. Altered 
ventricular torsion and transmural patterns of myocyte relaxation precede 
heart failure in aging f344 rats. American journal of physiology. Heart and 
circulatory physiology. 2013;305:H676-686 
3. Haynes P, Nava KE, Lawson BA, Chung CS, Mitov MI, Campbell SG, 
Stromberg AJ, Sadayappan S, Bonnell MR, Hoopes CW, Campbell KS. 
Transmural heterogeneity of cellular level power output is reduced in human 
heart failure. Journal of Molecular and Cellular Cardiology. 2014 Feb 20. pii: 
S0022-2828(14)00058-3. doi: 10.1016/j.yjmcc.2014.02.008. 
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4. Haynes P and Campbell KS. Myocardial hypertrophy reduces transmural 
variation in mitochondrial function. Invited Editorial. Submitted to Frontiers in 
Physiology: Striated Muscle, 12th March 2014. 
5. Zhang X, Haynes P, Campbell KS and Wenk JF. Numerical evaluation of 
myofiber orientation and transmural contractile strength on left ventricular 
function. Submitted to Medical Engineering & Physics, 23rd March 2014. 
Platform talks and seminars 
1. Myosin ATPase activity in Heart Failure. Muscle Forum, University of 
Kentucky, Lexington, KY: 16th Dec, 2010 
2. Decreased power output in failing human myocardium may reflect 
posttranslational modifications to sarcomeric proteins. Physiology Seminar 
Series, University of Kentucky, Lexington, KY: 11th May 2011 
3. Transmural variations in cellular level contractile function in the left ventricle 
of patients with end-stage heart failure. 8th Annual Spring Conference for UK 
Center for Clinical and Translational Science, Lexington, KY: 8th April 2013 
4. Cellular level contractile dysfunction and proteomic modifications in patients 
with end-stage heart failure. 1st Annual Utah Cardiac Recovery Symposium, 
Salt Lake City, Utah: 18th Jan 2013. 
5. Transmural heterogeneity of cellular level power output is reduced in human 
heart failure. Muscle Forum, University of Kentucky, Lexington, KY: 17th 
October 2013.  
Published Abstracts  
1. Shekar P, Mitov MI, Ferreira LF, Bonnell MR, Campbell KS. Measurements 
of power output in human myocardium. Biophysical journal. 2011;100:297a 
2. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Transmural 
heterogeneity and depressed function in the mechanical properties of 
ventricular tissue from patients with end-stage heart failure. Biophysical 
journal. 2012;102:352a 
3. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. 432 
transmural heterogeneity and depressed function in the mechanical 
properties of ventricular tissue from patients with end-stage heart failure. The 
Journal of Heart and Lung Transplantation. 2012;31:S153 
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4. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. 1243 
Alterations in phosphorylation of sarcomeric proteins contribute to the 
transmural differences and decrease in contractile function in patients with 
end-stage heart failure. American transplant congress 2012 abstracts. 
American Journal of Transplantation. 2012;12:27-542 
5. Haynes P, Mitov MI, Campbell SG, Lawson BA, Nava KE, Sadayappan S, 
Bonnell MR, Hoopes CW, Campbell KS. Alterations in proteins involved in 
cellular level contractile dysfunction in the left ventricles of patients with end 
stage heart failure. Biophysical journal. 2013;104:152a 
6. Haynes P, Mitov MI, Campbell SG, Lawson BA, Nava KE, Bonnell MR, 
Hoopes CW, Campbell KS. Myocyte power output in humans with end-stage 
heart failure: Effects of lvad treatment. Biophysical journal. 2013;104:152a-
153a 
7. Haynes P, Nava KE, Lawson BA, Chung CS, Mitov MI, Campbell SG, 
Stromberg AJ, Sadayappan S, Bonnell MR, Hoopes CW, Campbell KS. 
Transmural heterogeneity of cellular level power output is reduced in human 
heart failure. Circulation. 2013, 128:A13813 
Other Abstracts and Poster Presentations 
1. Shekar P, Osasona A, Peterson J, Reid E, Campbell KS. Direct 
measurements of ventricular stiffness in isolated rat hearts at 37°C. 12th 
Annual Gill Heart Institute Cardiovascular Research Day, Lexington, KY: 23rd 
October 2009 
2. Shekar P, Osasona A, Peterson J, Reid E, Campbell KS. Direct 
measurements of ventricular stiffness in isolated rat hearts at 37°C.1st Annual 
Center for Muscle Biology Retreat, Lexington, KY: 28th October 2009 
3. Shekar P, Gairola G, Campbell KS. Exposure to cigarette smoke impairs 
cardiac contractile function in mice. Physiology Research Retreat, Jabez, KY: 
18th Aug 2010  
4. Shekar P, Mitov MI, Ferreira LF, Bonnell MR, Campbell KS. Measurements 
of power output in human myocardium. 13th Annual Gill Heart Institute 
Cardiovascular Research Day, Lexington, KY: 22nd October 2010. 
5. Shekar P, Mitov MI, Ferreira LF, Bonnell MR, Campbell KS. Measurements 
of power output in human myocardium. 2nd Annual Center for Muscle Biology 
Retreat, Lexington, KY: 28th October 2010 
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6. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Decrease in 
transmural heterogeneity of the left ventricle may lead to alteration of dynamic 
properties in heart failure. Modeling workshop for Trainees in Muscle Biology, 
Lexington, KY: 28th July 2011 
7. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Transmural 
heterogeneity and depressed function in the mechanical properties of 
ventricular tissue from patients with end-stage heart failure.14th Annual Saha 
Heart Institute Cardiovascular Research Day, Lexington, KY: 21st October 
2011 
8. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Transmural 
heterogeneity and depressed function in the mechanical properties of 
ventricular tissue from patients with end-stage heart failure. 3rd Annual 
Center for Muscle Biology Retreat, Lexington, KY: 27th October 2011 
9. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Transmural 
heterogeneity and depressed function in the mechanical properties of 
ventricular tissue from patients with end-stage heart failure.7th Annual Spring 
Conference for UK Center for Clinical and Translational Science, Lexington, 
KY: 29th March, 2012 
10. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Transmural 
heterogeneity and depressed function in the mechanical properties of 
ventricular tissue from patients with end-stage heart failure. Bluegrass 
Molecular Biophysics Symposium, Lexington, KY: 11th May 2012 
11. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Transmural 
heterogeneity and depressed function in the mechanical properties of 
ventricular tissue from patients with end-stage heart failure. Gordon Research 
Seminar and Conference: Cardiac Regulatory Mechanisms, New London, 
NH: 9th June 2012 
12. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Transmural 
heterogeneity and depressed function in the mechanical properties of 
ventricular tissue from patients with end-stage heart failure. Physiology 
Research Retreat, Jabez, KY: 26th July 2012 
13. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Alterations in 
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proteins involved in cellular level contractile dysfunction in the left ventricles of 
patients with end-stage heart failure. 15th Annual Saha Heart Institute 
Cardiovascular Research Day, Lexington, KY: 5th October 2012 
14. Shekar P, Mitov MI, Ferreira LF, Campbell SG, Stasko SA, Jarrells AM, 
Lawson BA, Reid MB, Hoopes CW, Bonnell MR, Campbell KS. Alterations in 
proteins involved in cellular level contractile dysfunction in the left ventricles of 
patients with end-stage heart failure. 3rd Annual Center for Muscle Biology 
Retreat, Lexington, KY: 25th October 2012 
15. Haynes P, Mitov MI, Campbell SG, Lawson BA, Nava KE, Sadayappan S, 
Bonnell MR, Hoopes CW, Campbell KS. Cellular level contractile dysfunction 
and proteomic modifications in patients with end-stage heart failure. 1st 
Annual Utah Cardiac Recovery Symposium, Salt Lake City, Utah: 18th Jan 
2013 
16. Haynes P, Nava KE, Lawson BA, Chung CS, Mitov MI, Campbell SG, 
Stromberg AJ, Sadayappan S, Bonnell MR, Hoopes CW, Campbell KS. 
Transmural variations in cellular level contractile function in the left ventricle 
of patients with end-stage heart failure. 1st Annual Kentucky Physiological 
Society, American Physiological Society Chapter, Lexington, Kentucky: 25th 
March 2013 
17. Haynes P, Mitov MI, Campbell SG, Lawson BA, Nava KE, Sadayappan S, 
Bonnell MR, Hoopes CW, Campbell KS. Myocyte power output in humans 
with end-stage heart failure: effects of LVAD treatment. Bluegrass Molecular 
Biophysics Symposium, Lexington, KY: 20th May 2013 
18. Haynes P, Mitov MI, Campbell SG, Lawson BA, Nava KE, Sadayappan S, 
Bonnell MR, Hoopes CW, Campbell KS. Alterations in proteins involved in 
cellular level contractile dysfunction in the left ventricles of patients with end 
stage heart failure. Bluegrass Molecular Biophysics Symposium, Lexington, 
KY: 20th May 2013 
19. Haynes P, Nava KE, Lawson BA, Chung CS, Mitov MI, Campbell SG, 
Stromberg AJ, Sadayappan S, Bonnell MR, Hoopes CW, Campbell KS. 
Transmural heterogeneity of cellular level power output is reduced in human 
heart failure. 16th Annual Gill Heart Institute Cardiovascular Research Day, 
Lexington, KY: 11th October 2013 
20. Haynes P, Nava KE, Lawson BA, Chung CS, Mitov MI, Campbell SG, 
Stromberg AJ, Sadayappan S, Bonnell MR, Hoopes CW, Campbell KS. 
Transmural heterogeneity of cellular level power output is reduced in human 
heart failure. 5rth Annual Center for Muscle Biology Retreat, Lexington, KY: 7th 
Nov, 2013 
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